<SEC-DOCUMENT>0000950103-25-012484.txt : 20250930
<SEC-HEADER>0000950103-25-012484.hdr.sgml : 20250930
<ACCEPTANCE-DATETIME>20250929185755
ACCESSION NUMBER:		0000950103-25-012484
CONFORMED SUBMISSION TYPE:	424B2
PUBLIC DOCUMENT COUNT:		3
FILED AS OF DATE:		20250930
DATE AS OF CHANGE:		20250929

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CITIGROUP INC
		CENTRAL INDEX KEY:			0000831001
		STANDARD INDUSTRIAL CLASSIFICATION:	NATIONAL COMMERCIAL BANKS [6021]
		ORGANIZATION NAME:           	02 Finance
		EIN:				521568099
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B2
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-270327
		FILM NUMBER:		251357766

	BUSINESS ADDRESS:	
		STREET 1:		388 GREENWICH STREET
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10013
		BUSINESS PHONE:		2125591000

	MAIL ADDRESS:	
		STREET 1:		388 GREENWICH STREET
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10013

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	TRAVELERS GROUP INC
		DATE OF NAME CHANGE:	19950519

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	TRAVELERS INC
		DATE OF NAME CHANGE:	19940103

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PRIMERICA CORP /NEW/
		DATE OF NAME CHANGE:	19920703

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Citigroup Global Markets Holdings Inc.
		CENTRAL INDEX KEY:			0000200245
		STANDARD INDUSTRIAL CLASSIFICATION:	SECURITY BROKERS, DEALERS & FLOTATION COMPANIES [6211]
		ORGANIZATION NAME:           	02 Finance
		EIN:				112418067
		STATE OF INCORPORATION:			NY
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B2
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-270327-01
		FILM NUMBER:		251357767

	BUSINESS ADDRESS:	
		STREET 1:		388 GREENWICH ST
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10013
		BUSINESS PHONE:		212-816-6000

	MAIL ADDRESS:	
		STREET 1:		388 GREENWICH ST
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10013

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CITIGROUP GLOBAL MARKETS HOLDINGS INC
		DATE OF NAME CHANGE:	20030404

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SALOMON SMITH BARNEY HOLDINGS INC
		DATE OF NAME CHANGE:	19971128

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SALOMON INC
		DATE OF NAME CHANGE:	19920703
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B2
<SEQUENCE>1
<FILENAME>dp235134_424b2-us2514716.htm
<DESCRIPTION>PRELIMINARY PRICING SUPPLEMENT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 100%">
    <P STYLE="color: red; font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center">The information in this preliminary
    pricing supplement is not complete and may be changed. A registration statement relating to these securities has been filed with the Securities
    and Exchange Commission. This preliminary pricing supplement and the accompanying product supplement, prospectus supplement and prospectus
    are not an offer to sell these securities, nor are they soliciting an offer to buy these securities, in any state where the offer or sale
    is not permitted.</P>
    <P STYLE="color: red; font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center">SUBJECT TO COMPLETION, DATED SEPTEMBER
    29, 2025</P></TD></TR>
  </TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 53%; font-size: 10pt; color: #888888"><FONT STYLE="font-size: 18pt">Citigroup Global Markets Holdings Inc.</FONT></TD>
    <TD STYLE="width: 47%">
    <P STYLE="color: gray; font: bold 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: right">September&nbsp;&nbsp;&nbsp;&nbsp;
    , 2025</P>
    <P STYLE="color: gray; font: bold 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: right">Medium-Term Senior Notes, Series
    N</P>
    <P STYLE="color: gray; font: bold 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: right">Pricing Supplement No. 2025-USNCH28642</P>
    <P STYLE="color: gray; font: bold 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: right">Filed Pursuant to Rule 424(b)(2)</P>
    <P STYLE="color: gray; font: bold 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: right">Registration Statement Nos. 333-270327
    and 333-270327-01</P></TD></TR>
  </TABLE>
<P STYLE="color: #59AE43; font: 12pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">Autocallable Contingent Coupon Equity Linked Securities
Linked to the Worst Performing of Novo Nordisk A/S and Oracle Corporation Due October 5, 2028</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&squarf;</FONT></TD><TD>The securities offered by this pricing supplement are unsecured
debt securities issued by Citigroup Global Markets Holdings Inc. and guaranteed by Citigroup Inc. The securities offer the potential
for periodic contingent coupon payments at an annualized rate that, if all are paid, would produce a yield that is generally higher than
the yield on our conventional debt securities of the same maturity. In exchange for this higher potential yield, you must be willing
to accept the risks that (i) your actual yield may be lower than the yield on our conventional debt securities of the same maturity because
you may not receive one or more, or any, contingent coupon payments, (ii) the value of what you receive at maturity may be significantly
less than the stated principal amount of your securities, and may be zero, and (iii) the securities may be automatically called for redemption
prior to maturity beginning on the first potential autocall date specified below. Each of these risks will depend solely on the performance
of the <B>worst performing</B> of the underlyings specified below.</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&squarf;</FONT></TD><TD>You will be subject to risks associated with <U>each</U> of
the underlyings and will be negatively affected by adverse movements in <U>any one</U> of the underlyings. Although you will have downside
exposure to the worst performing underlying, you will not receive dividends with respect to any underlying or participate in any appreciation
of any underlying.</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&squarf;</FONT></TD><TD>Investors in the securities must be willing to accept (i) an
investment that may have limited or no liquidity and (ii) the risk of not receiving any payments due under the securities if we and Citigroup
Inc. default on our obligations. <B>All payments on the securities are subject to the credit risk of Citigroup Global Markets Holdings
Inc. and Citigroup Inc.</B></TD>
</TR></TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Arial, Helvetica, Sans-Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top; background-color: #59AE43">
    <TD COLSPAN="2" STYLE="font-size: 10pt"><FONT STYLE="color: white"><B>KEY TERMS</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 19%; font-size: 10pt"><FONT STYLE="font-size: 10pt; color: #59AE43"><B>Issuer:</B></FONT></TD>
    <TD STYLE="width: 81%; font-size: 10pt"><FONT STYLE="font-size: 10pt">Citigroup Global Markets Holdings Inc., a wholly owned subsidiary of Citigroup Inc.</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: #EAF3E5">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt; color: #59AE43"><B>Guarantee:</B></FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">All payments due on the securities are fully and unconditionally guaranteed by Citigroup Inc.</FONT></TD></TR>
  </TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Arial, Helvetica, Sans-Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="width: 19%; border-right: #59AE43 1pt solid"><FONT STYLE="font-size: 10pt; color: #59AE43"><B>Underlyings:</B></FONT></TD>
    <TD STYLE="width: 14%; border-top: #59AE43 1pt solid; border-right: #59AE43 1pt solid; border-bottom: #59AE43 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt; color: #59AE43"><B>Underlying</B></FONT></TD>
    <TD STYLE="width: 13%; border-top: #59AE43 1pt solid; border-right: #59AE43 1pt solid; border-bottom: #59AE43 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt; color: #59AE43"><B>Initial underlying value</B></FONT><B><FONT STYLE="color: #59AE43"><SUP>*</SUP></FONT></B></TD>
    <TD STYLE="width: 14%; border-top: #59AE43 1pt solid; border-right: #59AE43 1pt solid; border-bottom: #59AE43 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt; color: #59AE43"><B>Coupon barrier value</B></FONT><B><FONT STYLE="color: #59AE43"><SUP>**</SUP></FONT></B></TD>
    <TD STYLE="width: 14%; border-top: #59AE43 1pt solid; border-right: #59AE43 1pt solid; border-bottom: #59AE43 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt; color: #59AE43"><B>Autocall barrier value</B></FONT><B><FONT STYLE="color: #59AE43"><SUP>***</SUP></FONT></B></TD>
    <TD STYLE="width: 13%; border-top: #59AE43 1pt solid; border-right: #59AE43 1pt solid; border-bottom: #59AE43 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt; color: #59AE43"><B>Final barrier value</B></FONT><B><FONT STYLE="color: #59AE43"><SUP>****</SUP></FONT></B></TD>
    <TD STYLE="width: 13%; border-top: #59AE43 1pt solid; border-right: #59AE43 1pt solid; border-bottom: #59AE43 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt; color: #59AE43"><B>Equity ratio</B></FONT><B><FONT STYLE="color: #59AE43"><SUP>*****</SUP></FONT></B></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; border-right: #59AE43 1pt solid; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; border-right: #59AE43 1pt solid; border-bottom: #59AE43 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Novo Nordisk A/S</FONT></TD>
    <TD STYLE="vertical-align: bottom; border-right: #59AE43 1pt solid; border-bottom: #59AE43 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">$</FONT>&#9;</TD>
    <TD STYLE="vertical-align: bottom; border-right: #59AE43 1pt solid; border-bottom: #59AE43 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">$</FONT>&#9;</TD>
    <TD STYLE="vertical-align: bottom; border-right: #59AE43 1pt solid; border-bottom: #59AE43 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">$</FONT>&#9;</TD>
    <TD STYLE="vertical-align: bottom; border-right: #59AE43 1pt solid; border-bottom: #59AE43 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">$</FONT>&#9;</TD>
    <TD STYLE="vertical-align: bottom; border-right: #59AE43 1pt solid; border-bottom: #59AE43 1pt solid; text-align: center">&#9;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; border-right: #59AE43 1pt solid; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; border-right: #59AE43 1pt solid; border-bottom: #59AE43 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Oracle Corporation</FONT></TD>
    <TD STYLE="vertical-align: bottom; border-right: #59AE43 1pt solid; border-bottom: #59AE43 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">$</FONT>&#9;</TD>
    <TD STYLE="vertical-align: bottom; border-right: #59AE43 1pt solid; border-bottom: #59AE43 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">$</FONT>&#9;</TD>
    <TD STYLE="vertical-align: bottom; border-right: #59AE43 1pt solid; border-bottom: #59AE43 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">$</FONT>&#9;</TD>
    <TD STYLE="vertical-align: bottom; border-right: #59AE43 1pt solid; border-bottom: #59AE43 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">$</FONT>&#9;</TD>
    <TD STYLE="vertical-align: bottom; border-right: #59AE43 1pt solid; border-bottom: #59AE43 1pt solid; text-align: center">&#9;&#9;</TD></TR>
  </TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Arial, Helvetica, Sans-Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 19%">&nbsp;</TD>
    <TD STYLE="width: 81%">
    <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><SUP>*</SUP>For each underlying, its closing value on the pricing date</P>
    <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><SUP>**</SUP>For each underlying, 70.00% of its initial underlying value</P>
    <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><SUP>***</SUP>For each underlying, 80.00% of its initial underlying
    value</P>
    <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><SUP>****</SUP>For each underlying, 60.00% of its initial underlying
    value</P>
    <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><SUP>*****</SUP>For each underlying, the stated principal amount <I>divided
    by</I> its initial underlying value</P></TD></TR>
  <TR STYLE="vertical-align: top; background-color: #EAF3E5">
    <TD><FONT STYLE="font-size: 10pt; color: #59AE43"><B>Stated principal amount:</B></FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">$1,000 per security</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt; color: #59AE43"><B>Pricing date:</B></FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">September 30, 2025</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: #EAF3E5">
    <TD><FONT STYLE="font-size: 10pt; color: #59AE43"><B>Issue date:</B></FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">October 3, 2025</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt; color: #59AE43"><B>Valuation dates:</B></FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">December 30, 2025, March 30, 2026, June 30, 2026, September 30, 2026, December 30, 2026, March 30, 2027, June 30, 2027, September 30, 2027, December 30, 2027, March 30, 2028, June 30, 2028 and October 2, 2028 (the &ldquo;final valuation date&rdquo;), each subject to postponement if such date is not a scheduled trading day or certain market disruption events occur</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: #EAF3E5">
    <TD><FONT STYLE="font-size: 10pt; color: #59AE43"><B>Maturity date:</B></FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Unless earlier redeemed, October 5, 2028</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt; color: #59AE43"><B>Contingent coupon payment dates:</B></FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">The third business day after each valuation date, except that the contingent coupon payment date following the final valuation date will be the maturity date</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: #EAF3E5">
    <TD><FONT STYLE="font-size: 10pt; color: #59AE43"><B>Contingent coupon:</B></FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">On each contingent coupon payment date, unless previously redeemed, the securities will pay a contingent coupon equal to at least 5.3125% of the stated principal amount of the securities (equivalent to a contingent coupon rate of at least 21.25% per annum) (to be determined on the pricing date) <B>if and only if</B> the closing value of the worst performing underlying on the immediately preceding valuation date is greater than or equal to its coupon barrier value. <B>If the closing value of the worst performing underlying on any valuation date is less than its coupon barrier value, you will not receive any contingent coupon payment on the immediately following contingent coupon payment date. </B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt; color: #59AE43"><B>Payment at maturity:</B></FONT></TD>
    <TD>
    <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">If the securities are not automatically redeemed prior to maturity,
    you will receive at maturity for each security you then hold (in addition to the final contingent coupon payment, if applicable):</P>
    <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 26.35pt; text-indent: -8.5pt"><FONT STYLE="font-family: Wingdings">&sect;&#9;</FONT>If
    the final underlying value of the worst performing underlying on the final valuation date is <B>greater than or equal to</B> its final
    barrier value: $1,000</P>
    <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 26.35pt; text-indent: -8.5pt"><FONT STYLE="font-family: Wingdings">&sect;&#9;</FONT>If
    the final underlying value of the worst performing underlying on the final valuation date is <B>less than</B> its final barrier value:</P>
    <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 26.35pt">a fixed number of underlying shares of the worst performing
    underlying on the final valuation date equal to its equity ratio (or, if we elect, the cash value of those shares based on its final underlying
    value)</P>
    <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><B>If the securities are not automatically redeemed prior to maturity
    and the final underlying value of the worst performing underlying on the final valuation date is less than its final barrier value, you
    will receive underlying shares of the worst performing underlying on the final valuation date (or, in our sole discretion, cash) that
    will be worth significantly less than the stated principal amount of your securities, and possibly nothing, at maturity, and you will
    not receive any contingent coupon payment at maturity.</B></P></TD></TR>
  <TR STYLE="vertical-align: top; background-color: #EAF3E5">
    <TD><FONT STYLE="font-size: 10pt; color: #59AE43"><B>Listing:</B></FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">The securities will not be listed on any securities exchange</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt; color: #59AE43"><B>Underwriter:</B></FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Citigroup Global Markets Inc. (&ldquo;<B>CGMI</B>&rdquo;), an affiliate of the issuer, acting as principal</FONT></TD></TR>
  </TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Arial, Helvetica, Sans-Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top; background-color: #EAF3E5">
    <TD STYLE="width: 19%"><FONT STYLE="font-size: 10pt; color: #59AE43"><B>Underwriting fee and issue price:</B></FONT></TD>
    <TD STYLE="width: 26%; text-align: center"><FONT STYLE="font-size: 10pt; color: #59AE43"><B>Issue price<SUP>(1)</SUP></B></FONT></TD>
    <TD STYLE="width: 29%; text-align: center"><FONT STYLE="font-size: 10pt; color: #59AE43"><B>Underwriting fee<SUP>(2)</SUP></B></FONT></TD>
    <TD STYLE="width: 26%; text-align: center"><FONT STYLE="font-size: 10pt; color: #59AE43"><B>Proceeds to issuer</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt; color: #59AE43"><B>Per security:</B></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">$1,000.00</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">$35.00</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">$965.00</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: #EAF3E5">
    <TD><FONT STYLE="font-size: 10pt; color: #59AE43"><B>Total:</B></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">$</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: right"><I>(Key Terms continued on next page)</I></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">(1) Citigroup Global Markets Holdings Inc. currently expects that the
estimated value of the securities on the pricing date will be at least $888.50 per security, which will be less than the issue price.
The estimated value of the securities is based on CGMI&rsquo;s proprietary pricing models and our internal funding rate. It is not an
indication of actual profit to CGMI or other of our affiliates, nor is it an indication of the price, if any, at which CGMI or any other
person may be willing to buy the securities from you at any time after issuance. See &ldquo;Valuation of the Securities&rdquo; in this
pricing supplement.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">(2) For more information on the distribution of the securities, see
&ldquo;Supplemental Plan of Distribution&rdquo; in this pricing supplement. In addition to the underwriting fee, CGMI and its affiliates
may profit from expected hedging activity related to this offering, even if the value of the securities declines. See &ldquo;Use of Proceeds
and Hedging&rdquo; in the accompanying prospectus.</P>

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><B>Investing in the securities involves risks not associated with an
investment in conventional debt securities. See &ldquo;Summary Risk Factors&rdquo; beginning on page PS-6.</B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><B>Neither the Securities and Exchange Commission
nor any state securities commission has approved or disapproved of the securities or determined that this pricing supplement and the accompanying
product supplement, prospectus supplement and prospectus are truthful or complete. Any representation to the contrary is a criminal offense.</B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><B><I>You should read this pricing supplement together
with the accompanying product supplement, prospectus supplement and prospectus, which can be accessed via the hyperlinks below:</I></B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Arial, Helvetica, Sans-Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; text-align: center"><A HREF="https://www.sec.gov/Archives/edgar/data/200245/000095010323003814/dp190219_424b2-coba0410.htm" STYLE="color: rgb(89,174,67); text-decoration: underline"><FONT STYLE="font-size: 10pt; color: rgb(89,174,67)"><B>Product Supplement No. EA-04-10 dated March 7, 2023</B></FONT></A></TD>
    <TD STYLE="width: 50%; text-align: center"><A HREF="https://www.sec.gov/Archives/edgar/data/831001/000119312523063080/d470905d424b2.htm" STYLE="color: rgb(89,174,67); text-decoration: underline"><FONT STYLE="font-size: 10pt; color: #59AE43"><B>Prospectus Supplement and Prospectus each dated March 7, 2023</B></FONT></A></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><B>The securities are not bank deposits and are
not insured or guaranteed by the Federal Deposit Insurance Corporation or any other governmental agency, nor are they obligations of,
or guaranteed by, a bank.</B></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="border-bottom: #59AE40 1pt solid; width: 100%; font-size: 10pt; color: #888888; text-align: right"><FONT STYLE="font-size: 18pt">Citigroup Global Markets Holdings Inc.</FONT></TD></TR><TR STYLE="vertical-align: top"><TD STYLE="padding: 0pt; font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Arial, Helvetica, Sans-Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top; background-color: #59AE43">
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt; color: white"><B>KEY TERMS (continued)</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 23%"><FONT STYLE="color: #59AE43"><B>Automatic early redemption:</B></FONT></TD>
    <TD STYLE="width: 77%">If, on any potential autocall date, the closing value of the worst performing underlying on that potential autocall date is greater than or equal to&nbsp;&nbsp;its autocall barrier value, each security you then hold will be automatically called on that potential autocall date for redemption on the immediately following contingent coupon payment date for an amount in cash equal to $1,000 <I>plus</I> the related contingent coupon payment. <B>The automatic early redemption feature may significantly limit your potential return on the securities. If the worst performing underlying performs in a way that would otherwise be favorable, the securities are likely to be automatically called for redemption prior to maturity, cutting short your opportunity to receive contingent coupon payments. The securities may be automatically called for redemption as early as the first potential autocall date specified below.</B></TD></TR>
  <TR STYLE="vertical-align: top; background-color: #EAF3E5">
    <TD><FONT STYLE="color: #59AE43"><B>Potential autocall dates:</B></FONT></TD>
    <TD>The valuation dates scheduled to occur on March 30, 2026, June 30, 2026, September 30, 2026, December 30, 2026, March 30, 2027, June 30, 2027, September 30, 2027, December 30, 2027, March 30, 2028 and June 30, 2028</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="color: #59AE43"><B>Final underlying value:</B></FONT></TD>
    <TD>For each underlying, its closing value on the final valuation date</TD></TR>
  <TR STYLE="vertical-align: top; background-color: #EAF3E5">
    <TD><FONT STYLE="color: #59AE43"><B>Worst performing underlying:</B></FONT></TD>
    <TD>For any valuation date, the underlying with the lowest underlying return determined as of that valuation date</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="color: #59AE43"><B>Underlying return:</B></FONT></TD>
    <TD>For each underlying on any valuation date, (i) its closing value on that valuation date <I>minus</I> its initial underlying value, <I>divided by</I> (ii) its initial underlying value</TD></TR>
  <TR STYLE="vertical-align: top; background-color: #EAF3E5">
    <TD><FONT STYLE="color: #59AE43"><B>CUSIP / ISIN:</B></FONT></TD>
    <TD>17333MRU9 / US17333MRU98</TD></TR>
  </TABLE>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="width: 50%; font-size: 10pt; color: #59AE43">&nbsp;</TD><TD STYLE="width: 50%; text-align: right; font-size: 10pt; color: #59AE43"><FONT STYLE="font-size: 10pt">PS-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></FONT></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="border-bottom: #59AE40 1pt solid; width: 100%; font-size: 10pt; color: #888888; text-align: right"><FONT STYLE="font-size: 18pt">Citigroup Global Markets Holdings Inc.</FONT></TD></TR><TR STYLE="vertical-align: top"><TD STYLE="padding: 0pt; font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 14pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; color: #59AE43">Additional Information</P>

<P STYLE="font: 14pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; color: #59AE43">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><B>General.</B> The terms of the securities are set forth in the accompanying
product supplement, prospectus supplement and prospectus, as supplemented by this pricing supplement. The accompanying product supplement,
prospectus supplement and prospectus contain important disclosures that are not repeated in this pricing supplement. For example, the
accompanying product supplement contains important information about how the closing value of each underlying will be determined and about
adjustments that may be made to the terms of the securities upon the occurrence of market disruption events and other specified events
with respect to each underlying. It is important that you read the accompanying product supplement, prospectus supplement and prospectus
together with this pricing supplement before deciding whether to invest in the securities. Certain terms used but not defined in this
pricing supplement are defined in the accompanying product supplement.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><B>Closing Value.</B> The &ldquo;closing value&rdquo; of each underlying
on any date is the closing price of its underlying shares on such date, as provided in the accompanying product supplement. The &ldquo;underlying
shares&rdquo; of (i) Oracle Corporation are its shares of common stock and (ii) Novo Nordisk A/S are American Depositary Shares (&ldquo;ADSs&rdquo;)
representing its B shares. Please see the accompanying product supplement for more information.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="width: 50%; font-size: 10pt; color: #59AE43">&nbsp;</TD><TD STYLE="width: 50%; text-align: right; font-size: 10pt; color: #59AE43"><FONT STYLE="font-size: 10pt">PS-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></FONT></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="border-bottom: #59AE40 1pt solid; width: 100%; font-size: 10pt; color: #888888; text-align: right"><FONT STYLE="font-size: 18pt">Citigroup Global Markets Holdings Inc.</FONT></TD></TR><TR STYLE="vertical-align: top"><TD STYLE="padding: 0pt; font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 14pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; color: #59AE43">Hypothetical Examples</P>

<P STYLE="font: 14pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; color: #59AE43">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">The examples in the first section below illustrate how to determine
whether a contingent coupon will be paid and whether the securities will be automatically called for redemption following a valuation
date that is also a potential autocall date. The examples in the second section below illustrate how to determine the payment at maturity
on the securities, assuming the securities are not automatically redeemed prior to maturity. The examples are solely for illustrative
purposes, do not show all possible outcomes and are not a prediction of any payment that may be made on the securities.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">The examples below are based on the following hypothetical values and
do not reflect the actual initial underlying values, coupon barrier values, final barrier values, autocall barrier values or equity ratios
of the underlyings. For the actual initial underlying value, coupon barrier value, final barrier value, autocall barrier value and equity
ratio of each underlying, see the cover page of this pricing supplement. We have used these hypothetical values, rather than the actual
values, to simplify the calculations and aid understanding of how the securities work. However, you should understand that the actual
payments on the securities will be calculated based on the actual initial underlying value, coupon barrier value, final barrier value,
autocall barrier value and equity ratio of each underlying, and not the hypothetical values indicated below. For ease of analysis, figures
below have been rounded. The examples below assume that the contingent coupon rate is set at the lowest value indicated on the cover page
of this pricing supplement. The actual contingent coupon rate will be determined on the pricing date.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Arial, Helvetica, Sans-Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="width: 20%; border: #59AE43 1pt solid; text-align: center"><FONT STYLE="color: #59AE43"><B>Underlying</B></FONT></TD>
    <TD STYLE="width: 16%; border-top: #59AE43 1pt solid; border-right: #59AE43 1pt solid; border-bottom: #59AE43 1pt solid; text-align: center"><FONT STYLE="color: #59AE43"><B>Hypothetical initial underlying value</B></FONT></TD>
    <TD STYLE="width: 16%; border-top: #59AE43 1pt solid; border-right: #59AE43 1pt solid; border-bottom: #59AE43 1pt solid; text-align: center"><FONT STYLE="color: #59AE43"><B>Hypothetical coupon barrier value</B></FONT></TD>
    <TD STYLE="width: 16%; border-top: #59AE43 1pt solid; border-right: #59AE43 1pt solid; border-bottom: #59AE43 1pt solid; text-align: center"><FONT STYLE="color: #59AE43"><B>Hypothetical final barrier value</B></FONT></TD>
    <TD STYLE="width: 16%; border-top: #59AE43 1pt solid; border-right: #59AE43 1pt solid; border-bottom: #59AE43 1pt solid; text-align: center"><FONT STYLE="color: #59AE43"><B>Hypothetical autocall barrier value</B></FONT></TD>
    <TD STYLE="width: 16%; border-top: #59AE43 1pt solid; border-right: #59AE43 1pt solid; border-bottom: #59AE43 1pt solid; text-align: center"><FONT STYLE="color: #59AE43"><B>Hypothetical equity ratio</B></FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-right: #59AE43 1pt solid; border-bottom: #59AE43 1pt solid; border-left: #59AE43 1pt solid; text-align: center">Novo Nordisk A/S</TD>
    <TD STYLE="border-right: #59AE43 1pt solid; border-bottom: #59AE43 1pt solid; text-align: center">$100.00</TD>
    <TD STYLE="border-right: #59AE43 1pt solid; border-bottom: #59AE43 1pt solid; text-align: center">$70.00 (70.00% of its hypothetical initial underlying value)</TD>
    <TD STYLE="border-right: #59AE43 1pt solid; border-bottom: #59AE43 1pt solid; text-align: center">$60.00 (60.00% of its hypothetical initial underlying value)</TD>
    <TD STYLE="border-right: #59AE43 1pt solid; border-bottom: #59AE43 1pt solid; text-align: center">$80.00 (80.00% of its hypothetical initial underlying value)</TD>
    <TD STYLE="border-right: #59AE43 1pt solid; border-bottom: #59AE43 1pt solid; text-align: center">10.00000</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-right: #59AE43 1pt solid; border-bottom: #59AE43 1pt solid; border-left: #59AE43 1pt solid; text-align: center">Oracle Corporation</TD>
    <TD STYLE="border-right: #59AE43 1pt solid; border-bottom: #59AE43 1pt solid; text-align: center">$100.00</TD>
    <TD STYLE="border-right: #59AE43 1pt solid; border-bottom: #59AE43 1pt solid; text-align: center">$70.00 (70.00% of its hypothetical initial underlying value)</TD>
    <TD STYLE="border-right: #59AE43 1pt solid; border-bottom: #59AE43 1pt solid; text-align: center">$60.00 (60.00% of its hypothetical initial underlying value)</TD>
    <TD STYLE="border-right: #59AE43 1pt solid; border-bottom: #59AE43 1pt solid; text-align: center">$80.00 (80.00% of its hypothetical initial underlying value)</TD>
    <TD STYLE="border-right: #59AE43 1pt solid; border-bottom: #59AE43 1pt solid; text-align: center">10.00000</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; color: #59AE43">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; color: #59AE43"><B><I>Hypothetical Examples of Contingent Coupon Payments
and any Payment upon Automatic Early Redemption Following a Valuation Date that is also a Potential Autocall Date</I></B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; color: #59AE43">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">The three hypothetical examples below illustrate how to determine whether
a contingent coupon will be paid and whether the securities will be automatically redeemed following a hypothetical valuation date that
is also a potential autocall date, assuming that the closing values of the underlyings on the hypothetical valuation date are as indicated
below.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Arial, Helvetica, Sans-Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 25%; border: #59AE43 1pt solid; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 25%; border-top: #59AE43 1pt solid; border-right: #59AE43 1pt solid; border-bottom: #59AE43 1pt solid; text-align: center"><B>Hypothetical closing value of Novo Nordisk A/S on hypothetical valuation date</B></TD>
    <TD STYLE="width: 25%; border-top: #59AE43 1pt solid; border-right: #59AE43 1pt solid; border-bottom: #59AE43 1pt solid; text-align: center"><B>Hypothetical closing value of Oracle Corporation on hypothetical valuation date</B></TD>
    <TD STYLE="width: 25%; border-top: #59AE43 1pt solid; border-right: #59AE43 1pt solid; border-bottom: #59AE43 1pt solid; text-align: center"><B>Hypothetical payment per $1,000.00 security on related contingent coupon payment date</B></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-right: #59AE43 1pt solid; border-bottom: #59AE43 1pt solid; border-left: #59AE43 1pt solid; text-align: center"><FONT STYLE="color: #59AE43"><B>Example 1</B></FONT></TD>
    <TD STYLE="border-right: #59AE43 1pt solid; border-bottom: #59AE43 1pt solid; text-align: center">$120<BR>
(underlying return =<BR>
($120 - $100) / $100 = 20%)</TD>
    <TD STYLE="border-right: #59AE43 1pt solid; border-bottom: #59AE43 1pt solid; text-align: center">$75<BR>
(underlying return =<BR>
($75 - $100) / $100 = -25%)</TD>
    <TD STYLE="border-right: #59AE43 1pt solid; border-bottom: #59AE43 1pt solid; text-align: center"><B>$53.125</B><BR>
(contingent coupon is paid; securities not redeemed)</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-right: #59AE43 1pt solid; border-bottom: #59AE43 1pt solid; border-left: #59AE43 1pt solid; text-align: center"><FONT STYLE="color: #59AE43"><B>Example 2</B></FONT></TD>
    <TD STYLE="border-right: #59AE43 1pt solid; border-bottom: #59AE43 1pt solid; text-align: center">$45<BR>
(underlying return =<BR>
($45 - $100) / $100 = -55%)</TD>
    <TD STYLE="border-right: #59AE43 1pt solid; border-bottom: #59AE43 1pt solid; text-align: center">$120<BR>
(underlying return =<BR>
($120 - $100) / $100 = 20%)</TD>
    <TD STYLE="border-right: #59AE43 1pt solid; border-bottom: #59AE43 1pt solid; text-align: center"><B>$0.00</B><BR>
(no contingent coupon; securities not redeemed)</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-right: #59AE43 1pt solid; border-bottom: #59AE43 1pt solid; border-left: #59AE43 1pt solid; text-align: center"><FONT STYLE="color: #59AE43"><B>Example 3</B></FONT></TD>
    <TD STYLE="border-right: #59AE43 1pt solid; border-bottom: #59AE43 1pt solid; text-align: center">$110<BR>
(underlying return =<BR>
($110 - $100) / $100 = 10%)</TD>
    <TD STYLE="border-right: #59AE43 1pt solid; border-bottom: #59AE43 1pt solid; text-align: center">$115<BR>
(underlying return =<BR>
($115 - $100) / $100 = 15%)</TD>
    <TD STYLE="border-right: #59AE43 1pt solid; border-bottom: #59AE43 1pt solid; text-align: center"><B>$1,053.125</B><BR>
(contingent coupon is paid; securities redeemed)</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><FONT STYLE="color: #59AE43"><B>Example 1:</B></FONT> On the hypothetical
valuation date, Oracle Corporation has the lowest underlying return and, therefore, is the worst performing underlying on the hypothetical
valuation date. In this scenario, the closing value of the worst performing underlying on the hypothetical valuation date is greater than
its coupon barrier value but less than its autocall barrier value. As a result, investors in the securities would receive the contingent
coupon payment on the related contingent coupon payment date and the securities would not be automatically redeemed.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><FONT STYLE="color: #59AE43"><B>Example 2:</B></FONT> On the hypothetical
valuation date, Novo Nordisk A/S has the lowest underlying return and, therefore, is the worst performing underlying on the hypothetical
valuation date. In this scenario, the closing value of the worst performing underlying on the hypothetical valuation date is less than
its coupon barrier value. As a result, investors would not receive any payment on the related contingent coupon payment date and the securities
would not be automatically redeemed.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><B>Investors in the securities will not receive a contingent coupon
on the contingent coupon payment date following a valuation date if the closing value of the worst performing underlying on that valuation
date is less than its coupon barrier value. Whether a contingent coupon is paid following a valuation date depends solely on the closing
value of the worst performing underlying on that valuation date.</B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><FONT STYLE="color: #59AE43"><B>Example 3:</B></FONT> On the hypothetical
valuation date, Novo Nordisk A/S has the lowest underlying return and, therefore, is the worst performing underlying on the hypothetical
valuation date. In this scenario, the closing value of the worst performing underlying on the hypothetical valuation date is greater than
both its coupon barrier value and its autocall barrier value. As a result, the securities would be automatically redeemed on the related
contingent coupon payment date for an amount in cash equal to $1,000.00 <I>plus</I> the related contingent coupon payment.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">If the hypothetical valuation date were not also a potential autocall
date, the securities would not be automatically redeemed on the related contingent coupon payment date.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="width: 50%; font-size: 10pt; color: #59AE43">&nbsp;</TD><TD STYLE="width: 50%; text-align: right; font-size: 10pt; color: #59AE43"><FONT STYLE="font-size: 10pt">PS-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></FONT></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="border-bottom: #59AE40 1pt solid; width: 100%; font-size: 10pt; color: #888888; text-align: right"><FONT STYLE="font-size: 18pt">Citigroup Global Markets Holdings Inc.</FONT></TD></TR><TR STYLE="vertical-align: top"><TD STYLE="padding: 0pt; font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; color: #59AE43"><B><I>Hypothetical Examples of the Payment at Maturity
on the Securities</I></B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; color: #59AE43">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">The next four hypothetical examples illustrate the calculation of the
payment at maturity on the securities, assuming that the securities have not been earlier automatically redeemed and that the final underlying
values of the underlyings are as indicated below.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Arial, Helvetica, Sans-Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 25%; border: #59AE43 1pt solid; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 25%; border-top: #59AE43 1pt solid; border-right: #59AE43 1pt solid; border-bottom: #59AE43 1pt solid; text-align: center"><B>Hypothetical final underlying value of Novo Nordisk A/S</B></TD>
    <TD STYLE="width: 25%; border-top: #59AE43 1pt solid; border-right: #59AE43 1pt solid; border-bottom: #59AE43 1pt solid; text-align: center"><B>Hypothetical final underlying value of Oracle Corporation</B></TD>
    <TD STYLE="width: 25%; border-top: #59AE43 1pt solid; border-right: #59AE43 1pt solid; border-bottom: #59AE43 1pt solid; text-align: center"><B>Hypothetical payment at maturity per $1,000.00 security</B></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-right: #59AE43 1pt solid; border-bottom: #59AE43 1pt solid; border-left: #59AE43 1pt solid; text-align: center"><FONT STYLE="color: #59AE43"><B>Example 4</B></FONT></TD>
    <TD STYLE="border-right: #59AE43 1pt solid; border-bottom: #59AE43 1pt solid; text-align: center">$110<BR>
(underlying return =<BR>
($110 - $100) / $100 = 10%)</TD>
    <TD STYLE="border-right: #59AE43 1pt solid; border-bottom: #59AE43 1pt solid; text-align: center">$120<BR>
(underlying return =<BR>
($120 - $100) / $100 = 20%)</TD>
    <TD STYLE="border-right: #59AE43 1pt solid; border-bottom: #59AE43 1pt solid; text-align: center"><B>$1,053.125</B><BR>
(contingent coupon is paid)</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-right: #59AE43 1pt solid; border-bottom: #59AE43 1pt solid; border-left: #59AE43 1pt solid; text-align: center"><FONT STYLE="color: #59AE43"><B>Example 5</B></FONT></TD>
    <TD STYLE="border-right: #59AE43 1pt solid; border-bottom: #59AE43 1pt solid; text-align: center">$130<BR>
(underlying return =<BR>
($130 - $100) / $100 = 30%)</TD>
    <TD STYLE="border-right: #59AE43 1pt solid; border-bottom: #59AE43 1pt solid; text-align: center">$65<BR>
(underlying return =<BR>
($65 - $100) / $100 = -35%)</TD>
    <TD STYLE="border-right: #59AE43 1pt solid; border-bottom: #59AE43 1pt solid; text-align: center"><B>$1,000.00</B></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-right: #59AE43 1pt solid; border-bottom: #59AE43 1pt solid; border-left: #59AE43 1pt solid; text-align: center"><FONT STYLE="color: #59AE43"><B>Example 6</B></FONT></TD>
    <TD STYLE="border-right: #59AE43 1pt solid; border-bottom: #59AE43 1pt solid; text-align: center">$110<BR>
(underlying return =<BR>
($110 - $100) / $100 = 10%)</TD>
    <TD STYLE="border-right: #59AE43 1pt solid; border-bottom: #59AE43 1pt solid; text-align: center">$50<BR>
(underlying return =<BR>
($50 - $100) / $100 = -50%)</TD>
    <TD STYLE="border-right: #59AE43 1pt solid; border-bottom: #59AE43 1pt solid; text-align: center"><B>A number of underlying shares of the worst performing underlying on the final valuation date (or, in our sole discretion, cash) worth $500.00 based on its final underlying value</B></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-right: #59AE43 1pt solid; border-bottom: #59AE43 1pt solid; border-left: #59AE43 1pt solid; text-align: center"><FONT STYLE="color: #59AE43"><B>Example 7</B></FONT></TD>
    <TD STYLE="border-right: #59AE43 1pt solid; border-bottom: #59AE43 1pt solid; text-align: center">$0<BR>
(underlying return =<BR>
($0 - $100) / $100 = -100%)</TD>
    <TD STYLE="border-right: #59AE43 1pt solid; border-bottom: #59AE43 1pt solid; text-align: center">$60<BR>
(underlying return =<BR>
($60 - $100) / $100 = -40%)</TD>
    <TD STYLE="border-right: #59AE43 1pt solid; border-bottom: #59AE43 1pt solid; text-align: center"><B>$0.00</B></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><FONT STYLE="color: #59AE43"><B>Example 4:</B></FONT> On the final valuation
date, Novo Nordisk A/S has the lowest underlying return and, therefore, is the worst performing underlying on the final valuation date.
In this scenario, the final underlying value of the worst performing underlying on the final valuation date is greater than its final
barrier value and its coupon barrier value. Accordingly, at maturity, you would receive the stated principal amount of the securities
<I>plus</I> the contingent coupon payment due at maturity, but you would not participate in the appreciation of any of the underlyings.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><FONT STYLE="color: #59AE43"><B>Example 5:</B></FONT> On the final valuation
date, Oracle Corporation has the lowest underlying return and, therefore, is the worst performing underlying on the final valuation date.
In this scenario, the final underlying value of the worst performing underlying on the final valuation date is less than its coupon barrier
value but greater than its final barrier value. Accordingly, at maturity, you would receive the stated principal amount of the securities,
but would not receive any contingent coupon payment at maturity.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><FONT STYLE="color: #59AE43"><B>Example 6:</B></FONT> On the final valuation
date, Oracle Corporation has the lowest underlying return and, therefore, is the worst performing underlying on the final valuation date.
In this scenario, the final underlying value of the worst performing underlying on the final valuation date is less than its final barrier
value. Accordingly, at maturity, you would receive for each security you then hold a fixed number of underlying shares of the worst performing
underlying on the final valuation date equal to its equity ratio (or, at our option, the cash value thereof).</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">In this scenario, the value of a number of underlying shares of the
worst performing underlying on the final valuation date equal to its equity ratio, based on its final underlying value, would be $500.00.
Therefore, the value of the underlying shares of the worst performing underlying on the final valuation date (or, in our discretion, cash)
you receive at maturity would be significantly less than the stated principal amount of your securities. You would incur a loss based
on the depreciation of the worst performing underlying on the final valuation date. In addition, because the final underlying value of
the worst performing underlying on the final valuation date is below its coupon barrier value, you would not receive any contingent coupon
payment at maturity.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">If the final underlying value of the worst performing underlying on
the final valuation date is less than its final barrier value, we will have the option to deliver to you on the maturity date either a
number of underlying shares of the worst performing underlying on the final valuation date equal to its equity ratio or the cash value
of those underlying shares based on their final underlying value. The value of those underlying shares on the maturity date may be different
than their final underlying value.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><FONT STYLE="color: #59AE43"><B>Example 7:</B></FONT> On the final valuation
date, Novo Nordisk A/S has the lowest underlying return and, therefore, is the worst performing underlying on the final valuation date.
In this scenario, the underlying shares of the worst performing underlying on the final valuation date are worthless and you would lose
your entire investment in the securities at maturity. In addition, because the final underlying value of the worst performing underlying
on the final valuation date is below its coupon barrier value, you would not receive any contingent coupon payment at maturity.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><B>It is possible that the closing value of the worst performing underlying
will be less than its coupon barrier value on each valuation date and less than its final barrier value on the final valuation date, such
that you will not receive any contingent coupon payments over the term of the securities and will receive significantly less than the
stated principal amount of your securities, and possibly nothing, at maturity.</B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="width: 50%; font-size: 10pt; color: #59AE43">&nbsp;</TD><TD STYLE="width: 50%; text-align: right; font-size: 10pt; color: #59AE43"><FONT STYLE="font-size: 10pt">PS-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></FONT></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="border-bottom: #59AE40 1pt solid; width: 100%; font-size: 10pt; color: #888888; text-align: right"><FONT STYLE="font-size: 18pt">Citigroup Global Markets Holdings Inc.</FONT></TD></TR><TR STYLE="vertical-align: top"><TD STYLE="padding: 0pt; font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 14pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; color: #59AE43">Summary Risk Factors</P>

<P STYLE="font: 14pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; color: #59AE43">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">An investment in the securities is significantly riskier than an investment
in conventional debt securities. The securities are subject to all of the risks associated with an investment in our conventional debt
securities (guaranteed by Citigroup Inc.), including the risk that we and Citigroup Inc. may default on our obligations under the securities,
and are also subject to risks associated with each underlying. Accordingly, the securities are suitable only for investors who are capable
of understanding the complexities and risks of the securities. You should consult your own financial, tax and legal advisors as to the
risks of an investment in the securities and the suitability of the securities in light of your particular circumstances.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">The following is a summary of certain key risk factors for investors
in the securities. You should read this summary together with the more detailed description of risks relating to an investment in the
securities contained in the section &ldquo;Risk Factors Relating to the Securities&rdquo; beginning on page EA-7 in the accompanying product
supplement. You should also carefully read the risk factors included in the accompanying prospectus supplement and in the documents incorporated
by reference in the accompanying prospectus, including Citigroup Inc.&rsquo;s most recent Annual Report on Form 10-K and any subsequent
Quarterly Reports on Form 10-Q, which describe risks relating to the business of Citigroup Inc. more generally.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Wingdings">&sect;</FONT></TD><TD><B>You may lose a significant portion or all of your investment.</B> Unlike conventional debt securities, the securities do not provide
for the repayment of the stated principal amount at maturity in all circumstances. If the securities are not automatically redeemed prior
to maturity, your payment at maturity will depend on the final underlying value of the worst performing underlying on the final valuation
date. If the final underlying value of the worst performing underlying on the final valuation date is less than its final barrier value,
you will not receive the stated principal amount of your securities at maturity and, instead, will receive underlying shares of the worst
performing underlying on the final valuation date (or, in our sole discretion, cash based on its final underlying value) that will be
worth significantly less than the stated principal amount and possibly nothing. There is no minimum payment at maturity on the securities,
and you may lose up to all of your investment.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in">We may elect, in our sole discretion, to pay you cash at maturity
in lieu of delivering any underlying shares of the worst performing underlying on the final valuation date. If we elect to pay you cash
at maturity in lieu of delivering any underlying shares, the amount of that cash may be less than the market value of the underlying shares
on the maturity date because the market value will likely fluctuate between the final valuation date and the maturity date. Conversely,
if we do not exercise our cash election right and instead deliver underlying shares of the worst performing underlying on the final valuation
date to you on the maturity date, the market value of such underlying shares may be less than the cash amount you would have received
if we had exercised our cash election right. We will have no obligation to take your interests into account when deciding whether to exercise
our cash election right.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Wingdings">&sect;</FONT></TD><TD><B>You will not receive any contingent coupon on the contingent coupon payment date following any valuation date on which the closing
value of the worst performing underlying on that valuation date is less than its coupon barrier value.</B> A contingent coupon payment
will be made on a contingent coupon payment date if and only if the closing value of the worst performing underlying on the immediately
preceding valuation date is greater than or equal to its coupon barrier value. If the closing value of the worst performing underlying
on any valuation date is less than its coupon barrier value, you will not receive any contingent coupon payment on the immediately following
contingent coupon payment date. If the closing value of the worst performing underlying on each valuation date is below its coupon barrier
value, you will not receive any contingent coupon payments over the term of the securities.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Wingdings">&sect;</FONT></TD><TD><B>Higher contingent coupon rates are associated with greater risk.</B> The securities offer contingent coupon payments at an annualized
rate that, if all are paid, would produce a yield that is generally higher than the yield on our conventional debt securities of the same
maturity. This higher potential yield is associated with greater levels of expected risk as of the pricing date for the securities, including
the risk that you may not receive a contingent coupon payment on one or more, or any, contingent coupon payment dates and the risk that
the value of what you receive at maturity may be significantly less than the stated principal amount of your securities and may be zero.
The volatility of, and correlation between, the closing values of the underlyings are important factors affecting these risks. Greater
expected volatility of, and lower expected correlation between, the closing values of the underlyings as of the pricing date may result
in a higher contingent coupon rate, but would also represent a greater expected likelihood as of the pricing date that the closing value
of the worst performing underlying on one or more valuation dates will be less than its coupon barrier value, such that you will not receive
one or more, or any, contingent coupon payments during the term of the securities and that the final underlying value of the worst performing
underlying on the final valuation date will be less than its final barrier value, such that you will not be repaid the stated principal
amount of your securities at maturity.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Wingdings">&sect;</FONT></TD><TD><B>The securities are subject to heightened risk because they have multiple underlyings.</B> The securities are more risky than similar
investments that may be available with only one underlying. With multiple underlyings, there is a greater chance that any one underlying
will perform poorly, adversely affecting your return on the securities.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Wingdings">&sect;</FONT></TD><TD><B>The securities are subject to the risks of each of the underlyings and will be negatively affected if any one underlying performs
poorly.</B> You are subject to risks associated with each of the underlyings. If any one underlying performs poorly, you will be negatively
affected. The securities are not linked to a basket composed of the underlyings, where the blended performance of the underlyings would
be better than the performance of the worst performing underlying alone. Instead, you are subject to the full risks of whichever of the
underlyings is the worst performing underlying.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Wingdings">&sect;</FONT></TD><TD><B>You will not benefit in any way from the performance of any better performing underlying.</B> The return on the securities depends
solely on the performance of the worst performing underlying, and you will not benefit in any way from the performance of any better performing
underlying.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Wingdings">&sect;</FONT></TD><TD><B>You will be subject to risks relating to the relationship between the underlyings.</B> It is preferable from your perspective for
the underlyings to be correlated with each other, in the sense that their closing values tend to increase or decrease at similar times
and by similar magnitudes. By investing in the securities, you assume the risk that the underlyings will not exhibit this relationship.
The less</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</P>


<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="width: 50%; font-size: 10pt; color: #59AE43">&nbsp;</TD><TD STYLE="width: 50%; text-align: right; font-size: 10pt; color: #59AE43"><FONT STYLE="font-size: 10pt">PS-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></FONT></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="border-bottom: #59AE40 1pt solid; width: 100%; font-size: 10pt; color: #888888; text-align: right"><FONT STYLE="font-size: 18pt">Citigroup Global Markets Holdings Inc.</FONT></TD></TR><TR STYLE="vertical-align: top"><TD STYLE="padding: 0pt; font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">correlated the underlyings, the more likely
it is that any one of the underlyings will perform poorly over the term of the securities. All that is necessary for the securities to
perform poorly is for one of the underlyings to perform poorly. It is impossible to predict what the relationship between the underlyings
will be over the term of the securities. The underlyings differ in significant ways and, therefore, may not be correlated with each other.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Wingdings">&sect;</FONT></TD><TD><B>You may not be adequately compensated for assuming the downside risk of the worst performing underlying.</B> The potential contingent
coupon payments on the securities are the compensation you receive for assuming the downside risk of the worst performing underlying,
as well as all the other risks of the securities. That compensation is effectively &ldquo;at risk&rdquo; and may, therefore, be less than
you currently anticipate. First, the actual yield you realize on the securities could be lower than you anticipate because the coupon
is &ldquo;contingent&rdquo; and you may not receive a contingent coupon payment on one or more, or any, of the contingent coupon payment
dates. Second, the contingent coupon payments are the compensation you receive not only for the downside risk of the worst performing
underlying, but also for all of the other risks of the securities, including the risk that the securities may be automatically redeemed
prior to maturity, interest rate risk and our and Citigroup Inc.&rsquo;s credit risk. If those other risks increase or are otherwise greater
than you currently anticipate, the contingent coupon payments may turn out to be inadequate to compensate you for all the risks of the
securities, including the downside risk of the worst performing underlying.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Wingdings">&sect;</FONT></TD><TD><B>The securities may be automatically redeemed prior to maturity, limiting your opportunity to receive contingent coupon payments.</B>
On any potential autocall date, the securities will be automatically called for redemption if the closing value of the worst performing
underlying on that potential autocall date is greater than or equal to its autocall barrier value. As a result, if the worst performing
underlying performs in a way that would otherwise be favorable, the securities are likely to be automatically redeemed, cutting short
your opportunity to receive contingent coupon payments. If the securities are automatically redeemed prior to maturity, you may not be
able to reinvest your funds in another investment that provides a similar yield with a similar level of risk.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Wingdings">&sect;</FONT></TD><TD><B>The securities offer downside exposure to the worst performing underlying, but no upside exposure to any underlying.</B> You will
not participate in any appreciation in the value of any underlying over the term of the securities. Consequently, your return on the securities
will be limited to the contingent coupon payments you receive, if any, and may be significantly less than the return on any underlying
over the term of the securities. In addition, as an investor in the securities, you will not receive any dividends or other distributions
or have any other rights with respect to any of the underlyings.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Wingdings">&sect;</FONT></TD><TD><B>The performance of the securities will depend on the closing values of the underlyings solely on the valuation dates, which makes
the securities particularly sensitive to volatility in the closing values of the underlyings on or near the valuation dates.</B> Whether
the contingent coupon will be paid on any given contingent coupon payment date and whether the securities will be automatically redeemed
prior to maturity will depend on the closing values of the underlyings solely on the applicable valuation dates, regardless of the closing
values of the underlyings on other days during the term of the securities. If the securities are not automatically redeemed prior to maturity,
what you receive at maturity will depend solely on the closing value of the worst performing underlying on the final valuation date, and
not on any other day during the term of the securities. Because the performance of the securities depends on the closing values of the
underlyings on a limited number of dates, the securities will be particularly sensitive to volatility in the closing values of the underlyings
on or near the valuation dates. You should understand that the closing value of each underlying has historically been highly volatile.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Wingdings">&sect;</FONT></TD><TD><B>The securities are subject to the credit risk of Citigroup Global Markets Holdings Inc. and Citigroup Inc.</B> If we default on
our obligations under the securities and Citigroup Inc. defaults on its guarantee obligations, you may not receive anything owed to you
under the securities.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Wingdings">&sect;</FONT></TD><TD><B>The securities will not be listed on any securities exchange and you may not be able to sell them prior to maturity.</B> The securities
will not be listed on any securities exchange. Therefore, there may be little or no secondary market for the securities. CGMI currently
intends to make a secondary market in relation to the securities and to provide an indicative bid price for the securities on a daily
basis. Any indicative bid price for the securities provided by CGMI will be determined in CGMI&rsquo;s sole discretion, taking into account
prevailing market conditions and other relevant factors, and will not be a representation by CGMI that the securities can be sold at that
price, or at all. CGMI may suspend or terminate making a market and providing indicative bid prices without notice, at any time and for
any reason. If CGMI suspends or terminates making a market, there may be no secondary market at all for the securities because it is likely
that CGMI will be the only broker-dealer that is willing to buy your securities prior to maturity. Accordingly, an investor must be prepared
to hold the securities until maturity.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Wingdings">&sect;</FONT></TD><TD><B>The estimated value of the securities on the pricing date, based on CGMI&rsquo;s proprietary pricing models and our internal funding
rate, will be less than the issue price.</B> The difference is attributable to certain costs associated with selling, structuring and
hedging the securities that are included in the issue price. These costs include (i) any selling concessions or other fees paid in connection
with the offering of the securities, (ii) hedging and other costs incurred by us and our affiliates in connection with the offering of
the securities and (iii) the expected profit (which may be more or less than actual profit) to CGMI or other of our affiliates in connection
with hedging our obligations under the securities. These costs adversely affect the economic terms of the securities because, if they
were lower, the economic terms of the securities would be more favorable to you. The economic terms of the securities are also likely
to be adversely affected by the use of our internal funding rate, rather than our secondary market rate, to price the securities. See
&ldquo;The estimated value of the securities would be lower if it were calculated based on our secondary market rate&rdquo; below.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Wingdings">&sect;</FONT></TD><TD><B>The estimated value of the securities was determined for us by our affiliate using proprietary pricing models.</B> CGMI derived
the estimated value disclosed on the cover page of this pricing supplement from its proprietary pricing models. In doing so, it may have
made discretionary judgments about the inputs to its models, such as the volatility of, and correlation between, the closing values of
the underlyings, dividend yields on the underlyings and interest rates. CGMI&rsquo;s views on these inputs may differ from your or others&rsquo;
views, and as an underwriter in this offering, CGMI&rsquo;s interests may conflict with yours. Both the models and the inputs to the models
may prove to be wrong and therefore not an accurate reflection of the value of the securities. Moreover, the estimated value of the securities
set</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</P>


<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="width: 50%; font-size: 10pt; color: #59AE43">&nbsp;</TD><TD STYLE="width: 50%; text-align: right; font-size: 10pt; color: #59AE43"><FONT STYLE="font-size: 10pt">PS-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></FONT></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="border-bottom: #59AE40 1pt solid; width: 100%; font-size: 10pt; color: #888888; text-align: right"><FONT STYLE="font-size: 18pt">Citigroup Global Markets Holdings Inc.</FONT></TD></TR><TR STYLE="vertical-align: top"><TD STYLE="padding: 0pt; font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">forth on the cover page of this pricing
supplement may differ from the value that we or our affiliates may determine for the securities for other purposes, including for accounting
purposes. You should not invest in the securities because of the estimated value of the securities. Instead, you should be willing to
hold the securities to maturity irrespective of the initial estimated value.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Wingdings">&sect;</FONT></TD><TD><B>The estimated value of the securities would be lower if it were calculated based on our secondary market rate.</B> The estimated
value of the securities included in this pricing supplement is calculated based on our internal funding rate, which is the rate at which
we are willing to borrow funds through the issuance of the securities. Our internal funding rate is generally lower than our secondary
market rate, which is the rate that CGMI will use in determining the value of the securities for purposes of any purchases of the securities
from you in the secondary market. If the estimated value included in this pricing supplement were based on our secondary market rate,
rather than our internal funding rate, it would likely be lower. We determine our internal funding rate based on factors such as the costs
associated with the securities, which are generally higher than the costs associated with conventional debt securities, and our liquidity
needs and preferences. Our internal funding rate is not an interest rate that is payable on the securities.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in">Because there is not an active market for traded instruments
referencing our outstanding debt obligations, CGMI determines our secondary market rate based on the market price of traded instruments
referencing the debt obligations of Citigroup Inc., our parent company and the guarantor of all payments due on the securities, but subject
to adjustments that CGMI makes in its sole discretion. As a result, our secondary market rate is not a market-determined measure of our
creditworthiness, but rather reflects the market&rsquo;s perception of our parent company&rsquo;s creditworthiness as adjusted for discretionary
factors such as CGMI&rsquo;s preferences with respect to purchasing the securities prior to maturity.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Wingdings">&sect;</FONT></TD><TD><B>The estimated value of the securities is not an indication of the price, if any, at which CGMI or any other person may be willing
to buy the securities from you in the secondary market.</B> Any such secondary market price will fluctuate over the term of the securities
based on the market and other factors described in the next risk factor. Moreover, unlike the estimated value included in this pricing
supplement, any value of the securities determined for purposes of a secondary market transaction will be based on our secondary market
rate, which will likely result in a lower value for the securities than if our internal funding rate were used. In addition, any secondary
market price for the securities will be reduced by a bid-ask spread, which may vary depending on the aggregate stated principal amount
of the securities to be purchased in the secondary market transaction, and the expected cost of unwinding related hedging transactions.
As a result, it is likely that any secondary market price for the securities will be less than the issue price.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Wingdings">&sect;</FONT></TD><TD><B>The value of the securities prior to maturity will fluctuate based on many unpredictable factors.</B> The value of your securities
prior to maturity will fluctuate based on the closing values of the underlyings, the volatility of, and correlation between, the closing
values of the underlyings, dividend yields on the underlyings, interest rates generally, the time remaining to maturity and our and Citigroup
Inc.&rsquo;s creditworthiness, as reflected in our secondary market rate, among other factors described under &ldquo;Risk Factors Relating
to the Securities&mdash;Risk Factors Relating to All Securities&mdash;The value of your securities prior to maturity will fluctuate based
on many unpredictable factors&rdquo; in the accompanying product supplement. Changes in the closing values of the underlyings may not
result in a comparable change in the value of your securities. You should understand that the value of your securities at any time prior
to maturity may be significantly less than the issue price.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Wingdings">&sect;</FONT></TD><TD><B>Immediately following issuance, any secondary market bid price provided by CGMI, and the value that will be indicated on any brokerage
account statements prepared by CGMI or its affiliates, will reflect a temporary upward adjustment.</B> The amount of this temporary upward
adjustment will steadily decline to zero over the temporary adjustment period. See &ldquo;Valuation of the Securities&rdquo; in this pricing
supplement.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Wingdings">&sect;</FONT></TD><TD><B>Our offering of the securities is not a recommendation of any underlying.</B> The fact that we are offering the securities does
not mean that we believe that investing in an instrument linked to the underlyings is likely to achieve favorable returns. In fact, as
we are part of a global financial institution, our affiliates may have positions (including short positions) in the underlyings or in
instruments related to the underlyings, and may publish research or express opinions, that in each case are inconsistent with an investment
linked to the underlyings. These and other activities of our affiliates may affect the closing values of the underlyings in a way that
negatively affects the value of and your return on the securities.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Wingdings">&sect;</FONT></TD><TD><B>The closing value of an underlying may be adversely affected by our or our affiliates&rsquo; hedging and other trading activities.</B>
We expect to hedge our obligations under the securities through CGMI or other of our affiliates, who may take positions in the underlyings
or in financial instruments related to the underlyings and may adjust such positions during the term of the securities. Our affiliates
also take positions in the underlyings or in financial instruments related to the underlyings on a regular basis (taking long or short
positions or both), for their accounts, for other accounts under their management or to facilitate transactions on behalf of customers.
These activities could affect the closing values of the underlyings in a way that negatively affects the value of and your return on the
securities. They could also result in substantial returns for us or our affiliates while the value of the securities declines.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Wingdings">&sect;</FONT></TD><TD><B>We and our affiliates may have economic interests that are adverse to yours as a result of our affiliates&rsquo; business activities.</B>
Our affiliates engage in business activities with a wide range of companies. These activities include extending loans, making and facilitating
investments, underwriting securities offerings and providing advisory services. These activities could involve or affect the underlyings
in a way that negatively affects the value of and your return on the securities. They could also result in substantial returns for us
or our affiliates while the value of the securities declines. In addition, in the course of this business, we or our affiliates may acquire
non-public information, which will not be disclosed to you.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Wingdings">&sect;</FONT></TD><TD><B>The calculation agent, which is an affiliate of ours, will make important determinations with respect to the securities.</B> If
certain events occur during the term of the securities, such as market disruption events and other events with respect to an underlying,
CGMI, as calculation agent, will be required to make discretionary judgments that could significantly affect your return on the securities.
In making these judgments, the calculation agent&rsquo;s interests as an affiliate of ours could be adverse to your interests as a holder
of the securities. See &ldquo;Risk Factors Relating to the Securities&mdash;Risk Factors Relating to All Securities&mdash;The calculation
agent, which is an affiliate of ours, will make important determinations with respect to the securities&rdquo; in the accompanying product
supplement.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</P>


<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="width: 50%; font-size: 10pt; color: #59AE43">&nbsp;</TD><TD STYLE="width: 50%; text-align: right; font-size: 10pt; color: #59AE43"><FONT STYLE="font-size: 10pt">PS-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></FONT></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="border-bottom: #59AE40 1pt solid; width: 100%; font-size: 10pt; color: #888888; text-align: right"><FONT STYLE="font-size: 18pt">Citigroup Global Markets Holdings Inc.</FONT></TD></TR><TR STYLE="vertical-align: top"><TD STYLE="padding: 0pt; font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Wingdings">&sect;</FONT></TD><TD><B>Even if an underlying pays a dividend that it identifies as special or extraordinary, no adjustment will be required under the
securities for that dividend unless it meets the criteria specified in the accompanying product supplement.</B> In general, an adjustment
will not be made under the terms of the securities for any cash dividend paid by an underlying unless the amount of the dividend per share,
together with any other dividends paid in the same quarter, exceeds the dividend paid per share in the most recent quarter by an amount
equal to at least 10% of the closing value of that underlying on the date of declaration of the dividend. Any dividend will reduce the
closing value of the underlying by the amount of the dividend per share. If an underlying pays any dividend for which an adjustment is
not made under the terms of the securities, holders of the securities will be adversely affected. See &ldquo;Description of the Securities&mdash;Certain
Additional Terms for Securities Linked to an Underlying Company or an Underlying ETF&mdash;Dilution and Reorganization Adjustments&mdash;Certain
Extraordinary Cash Dividends&rdquo; in the accompanying product supplement.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Wingdings">&sect;</FONT></TD><TD><B>The securities will not be adjusted for all events that may have a dilutive effect on or otherwise adversely affect the closing
value of an underlying.</B> For example, we will not make any adjustment for ordinary dividends or extraordinary dividends that do not
meet the criteria described above, partial tender offers or additional underlying share issuances. Moreover, the adjustments we do make
may not fully offset the dilutive or adverse effect of the particular event. Investors in the securities may be adversely affected by
such an event in a circumstance in which a direct holder of the underlying shares of an underlying would not.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Wingdings">&sect;</FONT></TD><TD><B>The securities may become linked to an underlying other than an original underlying upon the occurrence of a reorganization event
or upon the delisting of the underlying shares of that original underlying.</B> For example, if an underlying enters into a merger agreement
that provides for holders of its underlying shares to receive shares of another entity and such shares are marketable securities, the
closing value of that underlying following consummation of the merger will be based on the value of such other shares. Additionally, if
the underlying shares of an underlying are delisted, the calculation agent may select a successor underlying. See &ldquo;Description of
the Securities&mdash;Certain Additional Terms for Securities Linked to an Underlying Company or an Underlying ETF&rdquo; in the accompanying
product supplement.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Wingdings">&sect;</FONT></TD><TD><B>The securities are subject to risks associated with non-U.S. companies.</B> An underlying is a non-U.S. company. The value of an
underlying, therefore, may be affected by political, economic, financial and social factors in the country where an underlying is located,
including changes in that country&rsquo;s governmental, economic and fiscal policies, currency exchange laws or other laws or restrictions.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Wingdings">&sect;</FONT></TD><TD><B>The securities are linked to ADSs and therefore are subject to currency exchange rate risk.</B> There are significant risks associated
with an investment linked to ADSs that are quoted and traded in U.S. dollars and represent an equity security issued by a foreign company.
If the equity security represented by the ADSs is traded in a foreign currency on a foreign exchange, the price of the ADSs will be affected
by fluctuations in the currency exchange rate between the U.S. dollar and the relevant foreign currency. In addition, if a significant
portion of the underlying&rsquo;s revenues or assets is denominated in one or more foreign currencies, changes in the exchange rate between
the U.S. dollar and those foreign currencies may affect the underlying&rsquo;s financial performance and, in turn, the price of the ADSs.
In recent years, the rate of exchange between the U.S. dollar and some other currencies has been highly volatile and this volatility may
continue in the future. These risks generally depend on economic and political events that cannot be predicted.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Wingdings">&sect;</FONT></TD><TD><B>There are important differences between the rights of holders of ADSs and the rights of holders of the equity securities represented
by the ADSs.</B> Because the securities are linked to the performance of ADSs representing an equity security issued by a foreign company
(the &ldquo;underlying equity&rdquo;), you should be aware that important differences exist between the rights of holders of ADSs and
an underlying equity. The ADSs are issued by a financial institution (the &ldquo;ADS depositary&rdquo;) under a deposit agreement, which
sets forth the rights and responsibilities of the ADS depositary, an underlying and holders of the ADSs. The rights of holders of ADSs
under that deposit agreement may be different from the rights of holders of the underlying equity. For example, the underlying may make
distributions in respect of its underlying equity that are not passed on to the holders of its ADSs. Any such differences between the
rights of holders of the ADSs and holders of the underlying equity may be significant and may materially and adversely affect the value
of the securities.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Wingdings">&sect;</FONT></TD><TD><B>If the underlying shares of an underlying are delisted, we may call the securities prior to maturity for an amount that may be
less than the stated principal amount.</B> If we exercise this call right, you will receive the amount described under &ldquo;Description
of the Securities&mdash;Certain Additional Terms for Securities Linked to an Underlying Company or an Underlying ETF&mdash;Delisting of
an Underlying Company&rdquo; in the accompanying product supplement. This amount may be less, and possibly significantly less, than the
stated principal amount of the securities.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Wingdings">&sect;</FONT></TD><TD><B>The U.S. federal tax consequences of an investment in the securities are unclear.</B> There is no direct legal authority regarding
the proper U.S. federal tax treatment of the securities, and we do not plan to request a ruling from the Internal Revenue Service (the
&ldquo;IRS&rdquo;). Consequently, significant aspects of the tax treatment of the securities are uncertain, and the IRS or a court might
not agree with the treatment of the securities as described in &ldquo;United States Federal Tax Considerations&rdquo; below. If the IRS
were successful in asserting an alternative treatment of the securities, the tax consequences of the ownership and disposition of the
securities might be materially and adversely affected. Moreover, future legislation, Treasury regulations or IRS guidance could adversely
affect the U.S. federal tax treatment of the securities, possibly retroactively.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in">Non-U.S. investors should note that persons having withholding
responsibility in respect of the securities may withhold on any coupon payment paid to a non-U.S. investor, generally at a rate of 30%.
To the extent that we have withholding responsibility in respect of the securities, we intend to so withhold.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in">You should read carefully the discussion under &ldquo;United
States Federal Tax Considerations&rdquo; and &ldquo;Risk Factors Relating to the Securities&rdquo; in the accompanying product supplement
and &ldquo;United States Federal Tax Considerations&rdquo; in this pricing supplement. You should also consult your tax adviser regarding
the U.S. federal tax consequences of an investment in the securities, as well as tax consequences arising under the laws of any state,
local or non-U.S. taxing jurisdiction.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="width: 50%; font-size: 10pt; color: #59AE43">&nbsp;</TD><TD STYLE="width: 50%; text-align: right; font-size: 10pt; color: #59AE43"><FONT STYLE="font-size: 10pt">PS-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></FONT></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="border-bottom: #59AE40 1pt solid; width: 100%; font-size: 10pt; color: #888888; text-align: right"><FONT STYLE="font-size: 18pt">Citigroup Global Markets Holdings Inc.</FONT></TD></TR><TR STYLE="vertical-align: top"><TD STYLE="padding: 0pt; font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 14pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; color: #59AE43">Information About Novo Nordisk A/S</P>

<P STYLE="font: 14pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; color: #59AE43">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><FONT STYLE="background-color: white">Novo Nordisk A/S is a healthcare
company engaged in the research, development, manufacturing and marketing of pharmaceutical products in various areas including diabetes
treatment</FONT>. The underlying shares of Novo Nordisk A/S are registered under the Securities Exchange Act of 1934, as amended (the
&ldquo;Exchange Act&rdquo;). Information provided to or filed with the SEC by Novo Nordisk A/S pursuant to the Exchange Act can be located
by reference to the SEC file number 333-82318 through the SEC&rsquo;s website at http://www.sec.gov. In addition, information regarding
Novo Nordisk A/S may be obtained from other sources including, but not limited to, press releases, newspaper articles and other publicly
disseminated documents. The underlying shares of Novo Nordisk A/S trade on the New York Stock Exchange under the ticker symbol &ldquo;NVO.&rdquo;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">We have derived all information regarding Novo Nordisk A/S from publicly
available information and have not independently verified any information regarding Novo Nordisk A/S. This pricing supplement relates
only to the securities and not to Novo Nordisk A/S. We make no representation as to the performance of Novo Nordisk A/S over the term
of the securities.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">The securities represent obligations of Citigroup Global Markets Holdings
Inc. (guaranteed by Citigroup Inc.) only. Novo Nordisk A/S is not involved in any way in this offering and has no obligation relating
to the securities or to holders of the securities.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; color: #59AE43">Historical Information</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; color: #59AE43">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">The closing value of Novo Nordisk A/S on September 25, 2025 was $56.04.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">The graph below shows the closing value of Novo Nordisk A/S for each
day such value was available from January 2, 2015 to September 25, 2025. We obtained the closing values from Bloomberg L.P., without independent
verification. If certain corporate transactions occurred during the historical period shown below, including, but not limited to, spin-offs
or mergers, then the closing values shown below for the period prior to the occurrence of any such transaction have been adjusted by Bloomberg
L.P. as if any such transaction had occurred prior to the first day in the period shown below. You should not take historical closing
values as an indication of future performance.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; background-color: #EAF3E0">
    <TD STYLE="width: 100%; border: #59AE43 1pt solid; text-align: center"><FONT STYLE="color: #59AE43"><B>Novo Nordisk A/S &ndash; Historical Closing Values</B></FONT><B><FONT STYLE="color: white"><BR>
</FONT><FONT STYLE="color: #59AE43">January 2, 2015 to September 25, 2025</FONT></B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: #59AE43 1pt solid; border-bottom: #59AE43 1pt solid; border-left: #59AE43 1pt solid; text-align: center"><IMG SRC="image_001.jpg" ALT="" STYLE="height: 315px; width: 577px"></TD></TR>
  </TABLE>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="width: 50%; font-size: 10pt; color: #59AE43">&nbsp;</TD><TD STYLE="width: 50%; text-align: right; font-size: 10pt; color: #59AE43"><FONT STYLE="font-size: 10pt">PS-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></FONT></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="border-bottom: #59AE40 1pt solid; width: 100%; font-size: 10pt; color: #888888; text-align: right"><FONT STYLE="font-size: 18pt">Citigroup Global Markets Holdings Inc.</FONT></TD></TR><TR STYLE="vertical-align: top"><TD STYLE="padding: 0pt; font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 14pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; color: #59AE43">Information About Oracle Corporation</P>

<P STYLE="font: 14pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; color: #59AE43">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">Oracle Corporation supplies software for enterprise information management.
The company offers databases and relational servers, application development and decision support tools, and enterprise business applications.
The underlying shares of Oracle Corporation are registered under the Securities Exchange Act of 1934, as amended (the &ldquo;Exchange
Act&rdquo;). Information provided to or filed with the SEC by Oracle Corporation pursuant to the Exchange Act can be located by reference
to the SEC file number 001-35992 through the SEC&rsquo;s website at http://www.sec.gov. In addition, information regarding Oracle Corporation
may be obtained from other sources including, but not limited to, press releases, newspaper articles and other publicly disseminated documents.
The underlying shares of Oracle Corporation trade on the New York Stock Exchange under the ticker symbol &ldquo;ORCL.&rdquo;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">We have derived all information regarding Oracle Corporation from publicly
available information and have not independently verified any information regarding Oracle Corporation. This pricing supplement relates
only to the securities and not to Oracle Corporation. We make no representation as to the performance of Oracle Corporation over the term
of the securities.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">The securities represent obligations of Citigroup Global Markets Holdings
Inc. (guaranteed by Citigroup Inc.) only. Oracle Corporation is not involved in any way in this offering and has no obligation relating
to the securities or to holders of the securities.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; color: #59AE43">Historical Information</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; color: #59AE43">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">The closing value of Oracle Corporation on September 25, 2025 was $291.33.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">The graph below shows the closing value of Oracle Corporation for each
day such value was available from January 2, 2015 to September 25, 2025. We obtained the closing values from Bloomberg L.P., without independent
verification. If certain corporate transactions occurred during the historical period shown below, including, but not limited to, spin-offs
or mergers, then the closing values shown below for the period prior to the occurrence of any such transaction have been adjusted by Bloomberg
L.P. as if any such transaction had occurred prior to the first day in the period shown below. You should not take historical closing
values as an indication of future performance.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; background-color: #EAF3E0">
    <TD STYLE="width: 100%; border: #59AE43 1pt solid; text-align: center"><FONT STYLE="color: #59AE43"><B>Oracle Corporation &ndash; Historical Closing Values</B></FONT><B><FONT STYLE="color: white"><BR>
</FONT><FONT STYLE="color: #59AE43">January 2, 2015 to September 25, 2025</FONT></B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: #59AE43 1pt solid; border-bottom: #59AE43 1pt solid; border-left: #59AE43 1pt solid; text-align: center"><IMG SRC="image_002.jpg" ALT="" STYLE="height: 315px; width: 577px"></TD></TR>
  </TABLE>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="width: 50%; font-size: 10pt; color: #59AE43">&nbsp;</TD><TD STYLE="width: 50%; text-align: right; font-size: 10pt; color: #59AE43"><FONT STYLE="font-size: 10pt">PS-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></FONT></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="border-bottom: #59AE40 1pt solid; width: 100%; font-size: 10pt; color: #888888; text-align: right"><FONT STYLE="font-size: 18pt">Citigroup Global Markets Holdings Inc.</FONT></TD></TR><TR STYLE="vertical-align: top"><TD STYLE="padding: 0pt; font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 14pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; color: #59AE43">United States Federal Tax Considerations</P>

<P STYLE="font: 14pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; color: #59AE43">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">You should read carefully the discussion under &ldquo;United States
Federal Tax Considerations&rdquo; and &ldquo;Risk Factors Relating to the Securities&rdquo; in the accompanying product supplement and
&ldquo;Summary Risk Factors&rdquo; in this pricing supplement.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">Due to the lack of any controlling legal authority, there is substantial
uncertainty regarding the U.S. federal tax consequences of an investment in the securities. In connection with any information reporting
requirements we may have in respect of the securities under applicable law, we intend (in the absence of an administrative determination
or judicial ruling to the contrary) to treat the securities for U.S. federal income tax purposes as prepaid forward contracts with associated
coupon payments that will be treated as gross income to you at the time received or accrued in accordance with your regular method of
tax accounting. In the opinion of our counsel, Davis Polk &amp; Wardwell LLP, this treatment of the securities is reasonable under current
law; however, our counsel has advised us that it is unable to conclude affirmatively that this treatment is more likely than not to be
upheld, and that alternative treatments are possible. Moreover, our counsel&rsquo;s opinion is based on market conditions as of the date
of this preliminary pricing supplement and is subject to confirmation on the pricing date.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">Assuming this treatment of the securities is respected and subject to
the discussion in &ldquo;United States Federal Tax Considerations&rdquo; in the accompanying product supplement, the following U.S. federal
income tax consequences should result under current law:</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Any coupon payments on the securities should be taxable as ordinary income to you at the time received or accrued in accordance with
your regular method of accounting for U.S. federal income tax purposes.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Upon a sale or exchange of a security (including retirement at maturity for cash), you should recognize capital gain or loss equal
to the difference between the amount realized and your tax basis in the security. For this purpose, the amount realized does not include
any coupon paid on retirement and may not include sale proceeds attributable to an accrued coupon, which may be treated as a coupon payment.
Such gain or loss should be long-term capital gain or loss if you held the security for more than one year.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>If, upon retirement of the securities, you receive underlying shares, you should not recognize gain or loss with respect to the underlying
shares received, other than any fractional underlying share for which you receive cash. Your basis in any underlying shares received,
including any fractional underlying share deemed received, should be equal to your tax basis in the securities. Your holding period for
any underlying shares received should start on the day after receipt. With respect to any cash received in lieu of a fractional share,
you should recognize capital loss in an amount equal to the difference between the amount of cash received in lieu of the fractional share
and the portion of your tax basis in the securities that is allocable to the fractional share.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial, Helvetica, Sans-Serif">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">We do not plan to request a ruling from the IRS regarding the treatment
of the securities. An alternative characterization of the securities could materially and adversely affect the tax consequences of ownership
and disposition of the securities, including the timing and character of income recognized. In addition, the U.S. Treasury Department
and the IRS have requested comments on various issues regarding the U.S. federal income tax treatment of &ldquo;prepaid forward contracts&rdquo;
and similar financial instruments and have indicated that such transactions may be the subject of future regulations or other guidance.
Furthermore, members of Congress have proposed legislative changes to the tax treatment of derivative contracts. Any legislation, Treasury
regulations or other guidance promulgated after consideration of these issues could materially and adversely affect the tax consequences
of an investment in the securities, possibly with retroactive effect. You should consult your tax adviser regarding possible alternative
tax treatments of the securities and potential changes in applicable law.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">This discussion does not address the U.S. federal tax consequences of
the ownership or disposition of the underlying shares that you may receive at maturity. You should consult your tax adviser regarding
the particular U.S. federal tax consequences of the ownership and disposition of the underlying shares.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><B>Withholding Tax on Non-U.S. Holders.</B> Because significant aspects
of the tax treatment of the securities are uncertain, persons having withholding responsibility in respect of the securities may withhold
on any coupon payment paid to Non-U.S. Holders (as defined in the accompanying product supplement), generally at a rate of 30%. To the
extent that we have (or an affiliate of ours has) withholding responsibility in respect of the securities, we intend to so withhold. In
order to claim an exemption from, or a reduction in, the 30% withholding, you may need to comply with certification requirements to establish
that you are not a U.S. person and are eligible for such an exemption or reduction under an applicable tax treaty. You should consult
your tax adviser regarding the tax treatment of the securities, including the possibility of obtaining a refund of any amounts withheld
and the certification requirement described above.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">As discussed under &ldquo;United States Federal Tax Considerations&mdash;Tax
Consequences to Non-U.S. Holders&rdquo; in the accompanying product supplement, Section 871(m) of the Code and Treasury regulations promulgated
thereunder (&ldquo;Section 871(m)&rdquo;) generally impose a 30% withholding tax on dividend equivalents paid or deemed paid to Non-U.S.
Holders with respect to certain financial instruments linked to U.S. equities (&ldquo;U.S. Underlying Equities&rdquo;) or indices that
include U.S. Underlying Equities. Section 871(m) generally applies to instruments that substantially replicate the economic performance
of one or more U.S. Underlying Equities, as determined based on tests set forth in the applicable Treasury regulations. However, the regulations,
as modified by an IRS notice, exempt financial instruments issued prior to January 1, 2027 that do not have a &ldquo;delta&rdquo; of one.
Based on the terms of the securities and representations provided by us as of the date of this preliminary pricing supplement, our counsel
is of the opinion that the securities should not be treated as transactions that have a &ldquo;delta&rdquo; of one within the meaning
of the regulations with respect to any U.S. Underlying Equity and, therefore, should not be subject to withholding tax under Section 871(m).
However, the final determination regarding the treatment of the securities under Section 871(m) will be made as of the pricing date for
the securities, and it is possible that the securities will be subject to withholding tax under Section 871(m) based on the circumstances
as of that date.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">A determination that the securities are not subject to Section 871(m)
is not binding on the IRS, and the IRS may disagree with this treatment. Moreover, Section 871(m) is complex and its application may depend
on your particular circumstances, including your other transactions. You should consult your tax adviser regarding the potential application
of Section 871(m) to the securities.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">We will not be required to pay any additional amounts with respect to
amounts withheld.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="width: 50%; font-size: 10pt; color: #59AE43">&nbsp;</TD><TD STYLE="width: 50%; text-align: right; font-size: 10pt; color: #59AE43"><FONT STYLE="font-size: 10pt">PS-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></FONT></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="border-bottom: #59AE40 1pt solid; width: 100%; font-size: 10pt; color: #888888; text-align: right"><FONT STYLE="font-size: 18pt">Citigroup Global Markets Holdings Inc.</FONT></TD></TR><TR STYLE="vertical-align: top"><TD STYLE="padding: 0pt; font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><B>You should read the section entitled &ldquo;United States Federal
Tax Considerations&rdquo; in the accompanying product supplement. The preceding discussion, when read in combination with that section,
constitutes the full opinion of Davis Polk &amp; Wardwell LLP regarding the material U.S. federal tax consequences of owning and disposing
of the securities.</B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><B>You should also consult your tax adviser regarding all aspects of
the U.S. federal income and estate tax consequences of an investment in the securities and any tax consequences arising under the laws
of any state, local or non-U.S. taxing jurisdiction.</B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 14pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; color: #59AE43">Supplemental Plan of Distribution</P>

<P STYLE="font: 14pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; color: #59AE43">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">CGMI, an affiliate of Citigroup Global Markets Holdings Inc. and the
underwriter of the sale of the securities, is acting as principal and will receive an underwriting fee of $35.00 for each security sold
in this offering. From this underwriting fee, CGMI will pay selected dealers not affiliated with CGMI a fixed selling concession of $35.00
for each security they sell. For the avoidance of doubt, any fees or selling concessions described in this pricing supplement will not
be rebated if the securities are automatically redeemed prior to maturity.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">See &ldquo;Plan of Distribution; Conflicts of Interest&rdquo; in the
accompanying product supplement and &ldquo;Plan of Distribution&rdquo; in each of the accompanying prospectus supplement and prospectus
for additional information.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 14pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; color: #59AE43">Valuation of the Securities</P>

<P STYLE="font: 14pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; color: #59AE43">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">CGMI calculated the estimated value of the securities set forth on the
cover page of this pricing supplement based on proprietary pricing models. CGMI&rsquo;s proprietary pricing models generated an estimated
value for the securities by estimating the value of a hypothetical package of financial instruments that would replicate the payout on
the securities, which consists of a fixed-income bond (the &ldquo;bond component&rdquo;) and one or more derivative instruments underlying
the economic terms of the securities (the &ldquo;derivative component&rdquo;). CGMI calculated the estimated value of the bond component
using a discount rate based on our internal funding rate. CGMI calculated the estimated value of the derivative component based on a proprietary
derivative-pricing model, which generated a theoretical price for the instruments that constitute the derivative component based on various
inputs, including the factors described under &ldquo;Summary Risk Factors&mdash;The value of the securities prior to maturity will fluctuate
based on many unpredictable factors&rdquo; in this pricing supplement, but not including our or Citigroup Inc.&rsquo;s creditworthiness.
These inputs may be market-observable or may be based on assumptions made by CGMI in its discretionary judgment.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">The estimated value of the securities is a function of the terms of
the securities and the inputs to CGMI&rsquo;s proprietary pricing models.&nbsp;&nbsp;As of the date of this preliminary pricing supplement,
it is uncertain what the estimated value of the securities will be on the pricing date because certain terms of the securities have not
yet been fixed and because it is uncertain what the values of the inputs to CGMI&rsquo;s proprietary pricing models will be on the pricing
date.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">For a period of approximately three months following issuance of the
securities, the price, if any, at which CGMI would be willing to buy the securities from investors, and the value that will be indicated
for the securities on any brokerage account statements prepared by CGMI or its affiliates (which value CGMI may also publish through one
or more financial information vendors), will reflect a temporary upward adjustment from the price or value that would otherwise be determined.
This temporary upward adjustment represents a portion of the hedging profit expected to be realized by CGMI or its affiliates over the
term of the securities. The amount of this temporary upward adjustment will decline to zero on a straight-line basis over the three-month
temporary adjustment period. However, CGMI is not obligated to buy the securities from investors at any time.&nbsp;&nbsp;See &ldquo;Summary
Risk Factors&mdash;The securities will not be listed on any securities exchange and you may not be able to sell them prior to maturity.&rdquo;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 14pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; color: #59AE43">Contact</P>

<P STYLE="font: 14pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; color: #59AE43">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">Clients may contact their local brokerage representative. Third-party
distributors may contact Citi Structured Investment Sales at (212) 723-7005.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&copy; 2025 Citigroup Global Markets Inc. All rights reserved. Citi
and Citi and Arc Design are trademarks and service marks of Citigroup Inc. or its affiliates and are used and registered throughout the
world.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 13; Options: Last -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="width: 50%; font-size: 10pt; color: #59AE43">&nbsp;</TD><TD STYLE="width: 50%; text-align: right; font-size: 10pt; color: #59AE43"><FONT STYLE="font-size: 10pt">PS-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></FONT></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $[ D$# 2(  A$! Q$!_\0
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M_P#Q5'VB^_Y[0?\ ?D__ !5)10 OVB^_Y[0?]^3_ /%4?:+[_GM!_P!^3_\
M%4E% "_:+[_GM!_WY/\ \51]HOO^>T'_ 'Y/_P 5244 +]HOO^>T'_?D_P#Q
M5'VB^_Y[0?\ ?D__ !5)10 OVB^_Y[0?]^3_ /%4?:+[_GM!_P!^3_\ %4E%
M "_:+[_GM!_WY/\ \51]HOO^>T'_ 'Y/_P 5244 +]HOO^>T'_?D_P#Q5'VB
M^_Y[0?\ ?D__ !5)10 OVB^_Y[0?]^3_ /%4?:+[_GM!_P!^3_\ %4E% "_:
M+[_GM!_WY/\ \51]HOO^>T'_ 'Y/_P 5244 +]HOO^>T'_?D_P#Q5'VB^_Y[
M0?\ ?D__ !5)10 OVB^_Y[0?]^3_ /%4?:+[_GM!_P!^3_\ %4E% "_:+[_G
MM!_WY/\ \51]HOO^>T'_ 'Y/_P 5244 +]HOO^>T'_?D_P#Q5'VB^_Y[0?\
M?D__ !5)10 OVB^_Y[0?]^3_ /%4?:+[_GM!_P!^3_\ %4E% "_:+[_GM!_W
MY/\ \51]HOO^>T'_ 'Y/_P 5244 +]HOO^>T'_?D_P#Q5'VB^_Y[0?\ ?D__
M !5)10 OVB^_Y[0?]^3_ /%4?:+[_GM!_P!^3_\ %4E% "_:+[_GM!_WY/\
M\51]HOO^>T'_ 'Y/_P 5244 +]HOO^>T'_?D_P#Q5'VB^_Y[0?\ ?D__ !5)
M10 OVB^_Y[0?]^3_ /%4?:+[_GM!_P!^3_\ %4E% "_:+[_GM!_WY/\ \51]
MHOO^>T'_ 'Y/_P 5244 +]HOO^>T'_?D_P#Q5'VB^_Y[0?\ ?D__ !5)10 O
MVB^_Y[0?]^3_ /%4?:+[_GM!_P!^3_\ %4E% "_:+[_GM!_WY/\ \51]HOO^
M>T'_ 'Y/_P 5244 +]HOO^>T'_?D_P#Q5'VB^_Y[0?\ ?D__ !5)10 OVB^_
MY[0?]^3_ /%4?:+[_GM!_P!^3_\ %4E% "_:+[_GM!_WY/\ \51]HOO^>T'_
M 'Y/_P 5244 +]HOO^>T'_?D_P#Q5'VB^_Y[0?\ ?D__ !5)10 OVB^_Y[0?
M]^3_ /%4?:+[_GM!_P!^3_\ %4E% "_:+[_GM!_WY/\ \51]HOO^>T'_ 'Y/
M_P 5244 +]HOO^>T'_?D_P#Q5'VB^_Y[0?\ ?D__ !5)10 OVB^_Y[0?]^3_
M /%4?:+[_GM!_P!^3_\ %4E% "_:+[_GM!_WY/\ \53[:ZN3>I#,\3(Z,WRQ
ME2""/<^M1T0?\A2#_KE)_-* -6BBB@ HHHH **CF1Y(61)#&Q& X )'YUSJW
M%[C33)))_P >\!5<L'E<GY_;@8)R#WZ=: .FKGM(_P"0/9_]<EJ;299WN'_>
M22-Y(,ZNQPLV3P,]._ [ 53TEI_['L\0Q_ZI?^6G_P!:@#2HJ+?<?\\8_P#O
MY_\ 6HWW'_/&/_OY_P#6H EHJ+?<?\\8_P#OY_\ 6HWW'_/&/_OY_P#6H EH
MJ+?<?\\8_P#OY_\ 6HWW'_/&/_OY_P#6H EHJ+?<?\\8_P#OY_\ 6HWW'_/&
M/_OY_P#6H EHJ+?<?\\8_P#OY_\ 6HWW'_/&/_OY_P#6H EHJ+?<?\\8_P#O
MY_\ 6HWW'_/&/_OY_P#6H EHJ+?<?\\8_P#OY_\ 6HWW'_/&/_OY_P#6H EH
MJ+?<?\\8_P#OY_\ 6HWW'_/&/_OY_P#6H EHJ+?<?\\8_P#OY_\ 6HWW'_/&
M/_OY_P#6H EHJ+?<?\\8_P#OY_\ 6HWW'_/&/_OY_P#6H EHJ+?<?\\8_P#O
MY_\ 6HWW'_/&/_OY_P#6H EHJ+?<?\\8_P#OY_\ 6HWW'_/&/_OY_P#6H EH
MJ+?<?\\8_P#OY_\ 6HWW'_/&/_OY_P#6H EHJ+?<?\\8_P#OY_\ 6HWW'_/&
M/_OY_P#6H EHJ+?<?\\8_P#OY_\ 6HWW'_/&/_OY_P#6H EHJ+?<?\\8_P#O
MY_\ 6HWW'_/&/_OY_P#6H EHJ+?<?\\8_P#OY_\ 6HWW'_/&/_OY_P#6H EH
MJ+?<?\\8_P#OY_\ 6HWW'_/&/_OY_P#6H EHJ+?<?\\8_P#OY_\ 6HWW'_/&
M/_OY_P#6H EHJ+?<?\\8_P#OY_\ 6HWW'_/&/_OY_P#6H EHJ+?<?\\8_P#O
MY_\ 6HWW'_/&/_OY_P#6H EHJ+?<?\\8_P#OY_\ 6HWW'_/&/_OY_P#6H EH
MJ+?<?\\8_P#OY_\ 6HWW'_/&/_OY_P#6H EHJ+?<?\\8_P#OY_\ 6HWW'_/&
M/_OY_P#6H EHJ+?<?\\8_P#OY_\ 6HWW'_/&/_OY_P#6H EHJ+?<?\\8_P#O
MY_\ 6HWW'_/&/_OY_P#6H EHJ+?<?\\8_P#OY_\ 6HWW'_/&/_OY_P#6H EH
MJ+?<?\\8_P#OY_\ 6HWW'_/&/_OY_P#6H EHJ+?<?\\8_P#OY_\ 6HWW'_/&
M/_OY_P#6H EHJ+?<?\\8_P#OY_\ 6HWW'_/&/_OY_P#6H EHJ+?<?\\8_P#O
MY_\ 6HWW'_/&/_OY_P#6H EHJ+?<?\\8_P#OY_\ 6HWW'_/&/_OY_P#6H EH
M@_Y"D'_7*3^:5%ON/^>,?_?S_P"M3K0R'58?,15_=28PV>Z^PH V**** "BB
MB@ HHHH *Y[2/^0/9_\ 7):Z&N>TC_D#V?\ UR6@"Y1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M* ):*B\N?_GX'_?H4>7/_P _ _[]"@"6BHO+G_Y^!_WZ%'ES_P#/P/\ OT*
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MNE64DD][&K147ES_ //P/^_0H\N?_GX'_?H5TFY+147ES_\ /P/^_0H\N?\
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M51-^:^XZRBBBO9/5"BBB@ H@_P"0I!_URD_FE%$'_(4@_P"N4G\TH U:***
M"BBB@!DTT<$32RMM11DFJAU6W$-O-MF,4ZJPD\LX4-]W=Z=:O5F+IUQ%'90)
M<Q-;VZ(K(\1)<K_%D-QTZ<\T 6+74(;N5XXQ(I W*77 =<XW+ZBLG2 ?['L^
M#_JEK1L],^S/F242*D7D1 +MVIGH3GD].>.E9&DVL!TBS)C'^J7N: -/!]#1
M@^AJ#[);_P#/(?F?\:/LEO\ \\A^9_QH GP?0T8/H:@^R6__ #R'YG_&C[);
M_P#/(?F?\: )\'T-&#Z&H/LEO_SR'YG_ !H^R6__ #R'YG_&@"?!]#1@^AJ#
M[);_ //(?F?\:/LEO_SR'YG_ !H GP?0T8/H:@^R6_\ SR'YG_&C[);_ //(
M?F?\: )\'T-&#Z&H/LEO_P \A^9_QH^R6_\ SR'YG_&@"?!]#1@^AJ#[);_\
M\A^9_P :/LEO_P \A^9_QH GP?0T8/H:@^R6_P#SR'YG_&C[);_\\A^9_P :
M )\'T-&#Z&H/LEO_ ,\A^9_QH^R6_P#SR'YG_&@"?!]#1@^AJ#[);_\ /(?F
M?\:/LEO_ ,\A^9_QH GP?0T8/H:@^R6__/(?F?\ &C[);_\ /(?F?\: )\'T
M-&#Z&H/LEO\ \\A^9_QH^R6__/(?F?\ &@"?!]#1@^AJ#[);_P#/(?F?\:/L
MEO\ \\A^9_QH GP?0T8/H:@^R6__ #R'YG_&C[);_P#/(?F?\: )\'T-&#Z&
MH/LEO_SR'YG_ !H^R6__ #R'YG_&@"?!]#1@^AJ#[);_ //(?F?\:/LEO_SR
M'YG_ !H GP?0T8/H:@^R6_\ SR'YG_&C[);_ //(?F?\: )\'T-&#Z&H/LEO
M_P \A^9_QH^R6_\ SR'YG_&@"?!]#1@^AJ#[);_\\A^9_P :/LEO_P \A^9_
MQH GP?0T8/H:@^R6_P#SR'YG_&C[);_\\A^9_P : )\'T-&#Z&H/LEO_ ,\A
M^9_QH^R6_P#SR'YG_&@"?!]#1@^AJ#[);_\ /(?F?\:/LEO_ ,\A^9_QH GP
M?0T8/H:@^R6__/(?F?\ &C[);_\ /(?F?\: )\'T-&#Z&H/LEO\ \\A^9_QH
M^R6__/(?F?\ &@"?!]#1@^AJ#[);_P#/(?F?\:/LEO\ \\A^9_QH GP?0T8/
MH:@^R6__ #R'YG_&C[);_P#/(?F?\: )\'T-&#Z&H/LEO_SR'YG_ !H^R6__
M #R'YG_&@"?!]#7"^-;F634XK(2MY2HK&/L&)//OQBNS^R6__/(?F?\ &N07
M2HM6\8WT;L1!;X)V'!R, #\\UR8M.4%"/5G-B4Y145U97UOPQ?+>HUI"]PDB
M*,HN-I  ^8].>M=K8120Z=:Q2(4=(E5E]"!S3OLEO_SR'YG_ !H^R6__ #R'
MYG_&M*="-.3E'J73HQA)R74PF4+\0HL*!_HA/ [X-0>'HQ;>*M9A++NS\HSU
M^;/]:U3H<)UQ=1W_ "B+R_)QQ]<YKC]?*67BQY(HQA&C?;DC)P,_G7-5O2M-
MK[7YHYZG[NTW_-^9Z-@^AHP?0U +6W(!\H#/;)_QH^R6_P#SR'YG_&O0.XGP
M?0T8/H:@^R6__/(?F?\ &C[);_\ /(?F?\: )\'T-) "-4@_ZY2?S2H?LEO_
M ,\A^9_QI]I#'%JL)1-N8I,\GU6@#8HHHH *XC4O%.KVLRNMWX<M;>2X>WB%
MQ/*[,RG!R54 8XSV![UV]>7W7@N\AN;Z-/#YNX+AB$:/5%18HR^YE4,F5W?Q
M=3@X!H ]%TZ2^DLU;48(8+G)#+#*70CL02 >?3%6ZI:2MTFG1I=VUO;2+D+#
M!(75%[#) R<>U7: "N>TC_D#V?\ UR6NAKGM(_Y ]G_UR6@"Y1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%%  .37->'!YFN:Y/ZS;?U-&MZXL_AR2YTV9P#,(6<J5([G'IVY
MIG@A0VGW<Y8M))/AB3GH/_KFN2513K1BNFOX'*YJ56,5ZG44445UG4%<QXOT
MJ*6R?48XV-S&5#,#QL'M^-=/535(_-TB\3&<PO\ RK*M!3@TS.K!2@TS+A\1
M*B:1#)$TLUZB[G! "G.,_GFM^O);&:1+ZT=7(*2)M)YV\UZV>IK#"UG53OTM
M^1CAJKJ)WZ"4445V'4%$'_(4@_ZY2?S2BB#_ )"D'_7*3^:4 :M%%% !7G'C
M#4]<M?%(CLM5AAA\H!$^W01+$2I^:17^8_-M/&1MR.M>CUY3XL:YU/5+HS:9
M>V]NR^6=VF6KR%1P661Y W/4''% 'J+R/';>8$,SA1\J8^8^V:S1K3M#!,+=
M?+:**68&3E!(< #CG'/I6I%CR4QG&T8S53^R;8"!5\P)"JH%#G#!?NAO7% #
M++4S<R[98EC1XO/B8/G*9QSP,'IZ]:R=)NK<:/9@SQ_ZI?XA6[:V$-I([QER
M6&!N;(1>NU?05D:1_P @>S_ZY+0!-]JM_P#GO'_WT*/M5O\ \]X_^^A4U% $
M/VJW_P">\?\ WT*/M5O_ ,]X_P#OH5-10!#]JM_^>\?_ 'T*/M5O_P ]X_\
MOH5-10!#]JM_^>\?_?0H^U6__/>/_OH5-10!#]JM_P#GO'_WT*/M5O\ \]X_
M^^A4U% $/VJW_P">\?\ WT*/M5O_ ,]X_P#OH5-10!#]JM_^>\?_ 'T*/M5O
M_P ]X_\ OH5-10!#]JM_^>\?_?0H^U6__/>/_OH5-10!#]JM_P#GO'_WT*/M
M5O\ \]X_^^A4U% $/VJW_P">\?\ WT*/M5O_ ,]X_P#OH5-10!#]JM_^>\?_
M 'T*/M5O_P ]X_\ OH5-10!#]JM_^>\?_?0H^U6__/>/_OH5-10!#]JM_P#G
MO'_WT*/M5O\ \]X_^^A4U% $/VJW_P">\?\ WT*/M5O_ ,]X_P#OH5-10!#]
MJM_^>\?_ 'T*/M5O_P ]X_\ OH5-10!#]JM_^>\?_?0H^U6__/>/_OH5-10!
M#]JM_P#GO'_WT*/M5O\ \]X_^^A4U% $/VJW_P">\?\ WT*/M5O_ ,]X_P#O
MH5-10!#]JM_^>\?_ 'T*/M5O_P ]X_\ OH5-10!#]JM_^>\?_?0H^U6__/>/
M_OH5-10!#]JM_P#GO'_WT*/M5O\ \]X_^^A4U% $/VJW_P">\?\ WT*/M5O_
M ,]X_P#OH5-10!#]JM_^>\?_ 'T*/M5O_P ]X_\ OH5-10!#]JM_^>\?_?0H
M^U6__/>/_OH5-10!#]JM_P#GO'_WT*/M5O\ \]X_^^A4U% $/VJW_P">\?\
MWT*/M5O_ ,]X_P#OH5-10!6EU"R@C,DMU"B#JQ:N:UKQ3-:7UQ:P+#+"T0V.
M,YRPY.<_6CQAJUI-8&P@N \WFCS%4< #/!/KG%<K=RF^O]\8+-($4 >NT#'Y
MUYN)Q+3Y(/\ K4\_$8AI\L&) ;BY6*PCDPK/D*S;5+'N>W:O3K=[*WB"1&WB
M'!*H0!G'M7(>'-$U&UUR">YLGCB16)9\8!Q@?C7=5>"IN,7*6Y>$@U%N6Y#]
MJM_^>\?_ 'T*/M5O_P ]X_\ OH5-17>=I#]JM_\ GO'_ -]"@W-JX*M-$5;@
M@L.14U% 'EIAC2PO9!MW)=(B$'G'S9Q^E>F"ZM]H_?Q]!_$*YWQ;:6]IH8%O
M D0DNE9]@QN.#R:Z@?='T%<>'I^SE*/I^IR4(<DG'T_4A^U6_P#SWC_[Z%'V
MJW_Y[Q_]]"IJ*[#K(?M5O_SWC_[Z%/M)HY=5A$<BMB*3.TY[K3Z(/^0I!_UR
MD_FE &K1110 5Y3XJL-(OM7N;S7[>^T>9F6-;R:U2X@VKD?*XR%W#!&<%2,U
MZM7 ZFO@K3=9E3Q%J4UY? ^9Y=^TDJ1ACD!4 V >G% '>1X\M=IR,#!]:=57
M3M1LM5L8[O3YTGMGX5TZ<<$8['VJU0 5SVD?\@>S_P"N2UT-<]I'_('L_P#K
MDM %RBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ H[URNI^+I-/UF:U6W26"+"GDABV.>>E=%87:ZA8P7:
M(RK,NX*>HK*%:$Y.,7JC.%6,I.*>J//VTR35?$]_;1,%822O]<'@?G@59\)Z
M5'>:A-)<;E:T9650<?/GOZCBMOPV!_;>N-@;A<<''(Y:M'2=&CTE[IUE,K7$
MF\DKC'7C]:X:6'3DI^;O^AQTZ";4_-_\ TZ***],] **** "BBB@#G/&O_($
MC_Z^%_D:U-6U$Z7I+WBQ>;MV@#.!SQG/I67XU!.AH "?WZ_R-<*;JX9'1IY&
M5P P+$@@=/RKS:]?V52275+]3@K5O9U)6ZI'IVC:E_:VFI=F+RBS%2N<\BK]
M8/@XY\.H/25_YUO5VT9.5--]CKI2<H)L*(/^0I!_URD_FE%$'_(4@_ZY2?S2
MM30U:*** "O,?%\T3^*KNWBWIF&+[6C:S':)<*0=HVLI.,9!((ZUZ=7DOB^:
MTM-<NHKG4+V>ZAC1W5;.T8E#N8METSA5P/<D <T >F:3IL&EVCQP,[>=*\[L
M[[B6<Y//Z?057U"_GM[]4C)\I!&7P!@;F*_-GGMQM_&M.+!B0C.-HZC%(]O#
M)*DLD,;2)]QF4$K]#VH S-.O;F68><WF+);B<*% ,9SC9QU_'T-9^DSD:/9_
MN)_]4O\ "/\ &NCCMX86=HHHT:0[G*J 6/J?6L+2/^0/9_\ 7): )_//_/"?
M_O@?XT>>?^>$_P#WP/\ &I:* (O//_/"?_O@?XT>>?\ GA/_ -\#_&I:* (O
M//\ SPG_ .^!_C1YY_YX3_\ ? _QJ6B@"+SS_P \)_\ O@?XT>>?^>$__? _
MQJ6B@"+SS_SPG_[X'^-'GG_GA/\ ]\#_ !J6B@"+SS_SPG_[X'^-'GG_ )X3
M_P#? _QJ6B@"+SS_ ,\)_P#O@?XT>>?^>$__ 'P/\:EHH B\\_\ /"?_ +X'
M^-'GG_GA/_WP/\:EHH B\\_\\)_^^!_C1YY_YX3_ /? _P :EHH B\\_\\)_
M^^!_C1YY_P">$_\ WP/\:EHH B\\_P#/"?\ [X'^-'GG_GA/_P!\#_&I:* (
MO//_ #PG_P"^!_C1YY_YX3_]\#_&I:* (O//_/"?_O@?XT>>?^>$_P#WP/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M]G_"I:* (LW/]R'_ +[/^%&;G^Y#_P!]G_"I:* (LW/]R'_OL_X49N?[D/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MPO\ A4M% $7E2_\ /RW_ 'PO^%'E2_\ /RW_ 'PO^%2T4 1>5+_S\M_WPO\
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MQ,#0?%*21P6E_*[3NS#SFP% [ G^M=7N!7<&&.N<\5S \#6?E2J;F8NW^K;
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MD=B22L@I%55&%4*/0#%+13&%%%% !1110 4444 %%%% !1110 4444 %%%%
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M_P :FHH A^RP_P!UO^^V_P :/LL/]UO^^V_QJ:B@"'[+#_=;_OMO\:/LL/\
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MC8_\_P!:_P#?Y?\ &@"S15;^T;'_ )_K7_O\O^-']HV/_/\ 6O\ W^7_ !H
MLT56_M&Q_P"?ZU_[_+_C1_:-C_S_ %K_ -_E_P : +-%5O[1L?\ G^M?^_R_
MXT?VC8_\_P!:_P#?Y?\ &@"S15;^T;'_ )_K7_O\O^-']HV/_/\ 6O\ W^7_
M !H LT56_M&Q_P"?ZU_[_+_C1_:-C_S_ %K_ -_E_P : +-%5O[1L?\ G^M?
M^_R_XT?VC8_\_P!:_P#?Y?\ &@"S15;^T;'_ )_K7_O\O^-']HV/_/\ 6O\
MW^7_ !H LT56_M&Q_P"?ZU_[_+_C1_:-C_S_ %K_ -_E_P : +-%5O[1L?\
MG^M?^_R_XT?VC8_\_P!:_P#?Y?\ &@"S15;^T;'_ )_K7_O\O^-']HV/_/\
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MEHL]I-=3?9=.\B'8IAF^RM'YB$#.25'?MWZT 5-:>]BOU1&4VK,F5A>%9(P
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M#L]2B@M].C1Y;@M-YEJRLA()!7*]VQ^9-:VO-IB:6TFK1>9;(ZMCRRY# \$
M G- #M-#,)$>:PG1,;#;1[<?49.*Q+^34%NY-L\093)LV/  IS\GWN=N/O\
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MT<,2H9&&W(P6R%?=V(QM(QW-6]+-A>:M=W]O) \Q41KY,VX-&<'<R]F+9'T
MJ'5[ZQTS[8OD.T]P58H\;^7(P &0V,9P!T]!0!+)<S)X66\,MH+CRE9Y1C9U
M&XJ3QG&<=LXJ#2VE^W0?Z=;W,,ZR%\*B@L"-NU0-P;'+9XYJZMMIT'AN*+,O
MV"&)&1CN+@+AE;U+ @'US5'3[RPU;7HKR&.4LL&89 DBY# ;O,!  /"@=^M
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"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $[ D$# 2(  A$! Q$!_\0
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M^Q1]JM_^>\?_ 'V* )OM%]_SV@_[\G_XJC[1??\ /:#_ +\G_P"*J'[5;_\
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M%]_SV@_[\G_XJC[1??\ /:#_ +\G_P"*J'[5;_\ />/_ +[%'VJW_P">\?\
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M]H/^_)_^*J'[5;_\]X_^^Q1]JM_^>\?_ 'V* )OM%]_SV@_[\G_XJC[1??\
M/:#_ +\G_P"*J'[5;_\ />/_ +[%'VJW_P">\?\ WV* )OM%]_SV@_[\G_XJ
MC[1??\]H/^_)_P#BJA^U6_\ SWC_ .^Q1]JM_P#GO'_WV* )OM%]_P ]H/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 40?\A2#_KE)_-**J:=J=I>Z[]GMY2TL$<@D&TC'S*.])M)V8FT
MM&=!1113&%%%% !1110 5SVD?\@>S_ZY+70USVD?\@>S_P"N2T 7**** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ '6N4\(_\ ([:I_NR_
M^C!75CK7*>$?^1VU3_=E_P#1@KFJ_P 2'J_R,*GQP]7^1Z!11172;A1110!6
MU!5>R</$\J\95%W'KZ9Y'MWK!2TN=ENKP2M*H1;:0H?DQ(2S'^YE=O'X5T]%
M &)I-O-%<.PB>)A"%F9U($DV3\WOWY]Q^%/21<?V/9X>'_5+_ ?\:Z>N>TC_
M ) ]G_UR6@"?%S_?A_[X/^-&+G^_#_WP?\:EHH BQ<_WX?\ O@_XT8N?[\/_
M 'P?\:EHH BQ<_WX?^^#_C1BY_OP_P#?!_QJ6B@"+%S_ 'X?^^#_ (T8N?[\
M/_?!_P :EHH BQ<_WX?^^#_C1BY_OP_]\'_&I:* (L7/]^'_ +X/^-&+G^_#
M_P!\'_&I:* (L7/]^'_O@_XT8N?[\/\ WP?\:EHH BQ<_P!^'_O@_P"-&+G^
M_#_WP?\ &I:* (L7/]^'_O@_XT8N?[\/_?!_QJ6B@"+%S_?A_P"^#_C1BY_O
MP_\ ?!_QJ6B@"+%S_?A_[X/^-&+G^_#_ -\'_&I:* (L7/\ ?A_[X/\ C1BY
M_OP_]\'_ !J6B@"+%S_?A_[X/^-&+G^_#_WP?\:EHH BQ<_WX?\ O@_XT8N?
M[\/_ 'P?\:EHH BQ<_WX?^^#_C1BY_OP_P#?!_QJ6B@"+%S_ 'X?^^#_ (T8
MN?[\/_?!_P :EHH BQ<_WX?^^#_C1BY_OP_]\'_&I:* (L7/]^'_ +X/^-&+
MG^_#_P!\'_&I:* (L7/]^'_O@_XT8N?[\/\ WP?\:EHH BQ<_P!^'_O@_P"-
M&+G^_#_WP?\ &I:* (L7/]^'_O@_XT8N?[\/_?!_QJ6B@"+%S_?A_P"^#_C1
MBY_OP_\ ?!_QJ6B@"+%S_?A_[X/^-&+G^_#_ -\'_&I:* (L7/\ ?A_[X/\
MC1BY_OP_]\'_ !J6B@"+%S_?A_[X/^-&+G^_#_WP?\:EHH BQ<_WX?\ O@_X
MT8N?[\/_ 'P?\:EHH BQ<_WX?^^#_C1BY_OP_P#?!_QJ6B@"+%S_ 'X?^^#_
M (T8N?[\/_?!_P :EHH BQ<_WX?^^#_C1BY_OP_]\'_&I:* (L7/]^'_ +X/
M^-&+G^_#_P!\'_&I:* (L7/]^'_O@_XT8N?[\/\ WP?\:EHH BQ<_P!^'_O@
M_P"-&+G^_#_WP?\ &I:* (@+G/WX?^^#_C7,^$,_\)IJ><9VR9Q_UT%=6.M<
MQX1C'_"6:I+DYW2)C_@8-<]7^)#U?Y&%3XX>K_([RBBBN@W"BBB@ HHHH *Y
M[2/^0/9_]<EKH:Y[2/\ D#V?_7): +E%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 #K7-^$?^1EU7_KK)_Z$*Z0=:YOPC_R,NJ_]=9/_
M $(5A4_B0^?Y&,_CA\_R.YHHHK<V"BBB@".:0Q1%UC>1NR)U/YUG)KD4EU%;
M+"_G/G<K.BE,,5/5N>0>F>E7[J*6>V>.&<P2-TD"AB/P-5/[,=HHHGN28UQO
M18PH;#;ACN* )+/4H[R4HL<B93S(R^,2)G&X8/\ /U%96D?\@>SY_P"62UJ6
MFF+;2,S2&50GE1JR@!$S]WW_ /K5CZ3;0'1[,F"/_5+_  "@#1S[T9]ZB^RV
M_P#SPB_[X%'V6W_YX1?]\"@"7/O1GWJ+[+;_ //"+_O@4?9;?_GA%_WP* )<
M^]&?>HOLMO\ \\(O^^!1]EM_^>$7_? H ES[T9]ZB^RV_P#SPB_[X%'V6W_Y
MX1?]\"@"7/O1GWJ+[+;_ //"+_O@4?9;?_GA%_WP* )<^]&?>HOLMO\ \\(O
M^^!1]EM_^>$7_? H ES[T9]ZB^RV_P#SPB_[X%'V6W_YX1?]\"@"7/O1GWJ+
M[+;_ //"+_O@4?9;?_GA%_WP* )<^]&?>HOLMO\ \\(O^^!1]EM_^>$7_? H
M ES[T9]ZB^RV_P#SPB_[X%'V6W_YX1?]\"@"7/O1GWJ+[+;_ //"+_O@4?9;
M?_GA%_WP* )<^]&?>HOLMO\ \\(O^^!1]EM_^>$7_? H ES[T9]ZB^RV_P#S
MPB_[X%'V6W_YX1?]\"@"7/O1GWJ+[+;_ //"+_O@4?9;?_GA%_WP* )<^]&?
M>HOLMO\ \\(O^^!1]EM_^>$7_? H ES[T9]ZB^RV_P#SPB_[X%'V6W_YX1?]
M\"@"7/O1GWJ+[+;_ //"+_O@4?9;?_GA%_WP* )<^]&?>HOLMO\ \\(O^^!1
M]EM_^>$7_? H ES[T9]ZB^RV_P#SPB_[X%'V6W_YX1?]\"@"7/O1GWJ+[+;_
M //"+_O@4?9;?_GA%_WP* )<^]&?>HOLMO\ \\(O^^!1]EM_^>$7_? H ES[
MT9]ZB^RV_P#SPB_[X%'V6W_YX1?]\"@"7/O1GWJ+[+;_ //"+_O@4?9;?_GA
M%_WP* )<^]&?>HOLMO\ \\(O^^!1]EM_^>$7_? H ES[T9]ZB^RV_P#SPB_[
MX%'V6W_YX1?]\"@"7/O1GWJ+[+;_ //"+_O@4?9;?_GA%_WP* )<^]&?>HOL
MMO\ \\(O^^!1]EM_^>$7_? H ES[T9]ZB^RV_P#SPB_[X%'V6W_YX1?]\"@"
M7/O1GWJ+[+;_ //"+_O@4?9;?_GA%_WP* )<^]&?>HOLMO\ \\(O^^!1]EM_
M^>$7_? H ES[T9]ZB^RV_P#SPB_[X%'V6W_YX1?]\"@"7/O1GWJ+[+;_ //"
M+_O@4?9;?_GA%_WP* ,+Q#KT^EW]G;P  /AY"0#N7.,#T/!IOA$@^)=5(.09
M),?]]"N4UN%SKNHA%)6*0DX'"C('X<D5T'P\ ^WW!QSL/]*\N%64\19[7?Y6
M/.A4E.O9^?\ D>B4445ZAZ(5Q&I>*=7M9E=;OPY:V\EP]O$+B>5V9E.#DJH
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MY]F_[[7_ !H EHJ+S9?^?9O^^U_QH\V7_GV;_OM?\: ):*B\V7_GV;_OM?\
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M*;(H!;Q[')++GJ>!@].F>_-9>DVT9T>S.9/]4O\ RT;_ !KIZY[2/^0/9_\
M7): )OLT?K)_W];_ !H^S1^LG_?UO\:FHH A^S1^LG_?UO\ &C[-'ZR?]_6_
MQJ:B@"'[-'ZR?]_6_P :/LT?K)_W];_&IJ* (?LT?K)_W];_ !H^S1^LG_?U
MO\:FHH A^S1^LG_?UO\ &C[-'ZR?]_6_QJ:B@"'[-'ZR?]_6_P :/LT?K)_W
M];_&IJ* (?LT?K)_W];_ !H^S1^LG_?UO\:FHH A^S1^LG_?UO\ &C[-'ZR?
M]_6_QJ:B@"'[-'ZR?]_6_P :/LT?K)_W];_&IJ* (?LT?K)_W];_ !H^S1^L
MG_?UO\:FHH A^S1^LG_?UO\ &C[-'ZR?]_6_QJ:B@"'[-'ZR?]_6_P :/LT?
MK)_W];_&IJ* (?LT?K)_W];_ !H^S1^LG_?UO\:FHH A^S1^LG_?UO\ &C[-
M'ZR?]_6_QJ:B@"'[-'ZR?]_6_P :/LT?K)_W];_&IJ* (?LT?K)_W];_ !H^
MS1^LG_?UO\:FHH A^S1^LG_?UO\ &C[-'ZR?]_6_QJ:B@"'[-'ZR?]_6_P :
M/LT?K)_W];_&IJ* (?LT?K)_W];_ !H^S1^LG_?UO\:FHH A^S1^LG_?UO\
M&C[-'ZR?]_6_QJ:B@"'[-'ZR?]_6_P :/LT?K)_W];_&IJ* (?LT?K)_W];_
M !H^S1^LG_?UO\:FHH A^S1^LG_?UO\ &C[-'ZR?]_6_QJ:B@"'[-'ZR?]_6
M_P :/LT?K)_W];_&IJ* (?LT?K)_W];_ !H^S1^LG_?UO\:FHH A^S1^LG_?
MUO\ &C[-'ZR?]_6_QJ:B@"'[-'ZR?]_6_P :/LT?K)_W];_&IJ* (?LT?K)_
MW];_ !H^S1^LG_?UO\:FHZ#- $/V:/UD_P"_K?XUBZ]J\6BM$@MY)GE4L#]H
M8 8]>:WHY(Y4WQNCK_>1@1^8KD_$5@NI>*;"T:0QK) ?F R1@L?Z5SUY2C"\
M-]#"M*2A[FY8M]:L=0T2[ED+P2QQ,'5I6(R0<;>>:G\*0(_ARW+;\[GZ.P_B
M/H:Y*30W3Q&ND^86RX D YVD9SCZ5Z%I]A#IMDEK 7,:Y.7.3D]:PP\JDYWF
MMM/F8T)3G.\NFA)]FC]9/^_K?XTTV<)1UPX# YQ(PSG\:L45WG:>8:6_V:>]
M@E3:LEM(IWDKC )'Z@=:ZWPE8HF@I*Q;=,[.=KD# X'3Z5B>-XPFL12@<R0C
M)]2"1_A78:/ EMHUG%'G:(E//J1D_J:\W#0Y:KC_ "W_ !//P\.6JX_R_J3_
M &:/UD_[^M_C3[2)8]5A*[N8I/O.3W7U-/H@_P"0I!_URD_FE>D>@:M%%% !
M1110 4444 %<]I'_ "![/_KDM=#7/:1_R![/_KDM %RBBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KDF\
M0_8O%=ZEW/*+)%**@Y 8 <X_.NMK@)M(N-?UK5);5XQY<^T[S@$=,_I7)B93
M7+R;W_0YL1*2Y>3>YK^)M>":1;MI]R5DN"'#)U"C^1SCBNCM2S6<#,Q9C&I)
M/4G KS34- U#38I);B$"!6V^:&&&R<#'>MR?Q5&_AH0Q2/%?A%0[00  <9!^
M@K"GB&IR=7338QA7:E)U---CM*SM?9DT"^=&966+(*G!'-<OX6ENK+5YK>YE
M9(C 9F#'(;@$-GZ&L&34;R6>XE:9W:Y4H^?XAZ8_*JJ8M>SVWNASQ2Y-M[FM
MH&J3:'-Y-Q_QZSP^<J 9Y(^7'IG&#4VCZA>:UXKMKJ9$/E*V0G 1<'\^35F^
M\.WNH:1I36YB,D-N$96.T\\CFMK1?#]OHQ:5)'DF= K,V,#N<?Y[5G3I57*,
M?LJS(ITZEU'[*U'MI+GQ,NJ^:GEB'R_+P=V<8S6K117I1BHWMU.^,5&]NH44
M4511ROC'2+J_^SW%I$TIC4HZ+UY/&!WKH[%633[9'4JRQ("#U! %3T5E&DHS
M<UU,XTU&;FNH40?\A2#_ *Y2?S2BB#_D*0?]<I/YI6IH:M%%% !1110 R8RB
M%O)"&3'RAS@9]ZQ5U2\DMK><%!B""65 G^L,AP0#GC&/?K6[5<V-J6A8V\68
M!B([1\@]O2@"EI]]<RS#SR'26 7"A4P4YQMZ\_\ UC6;I,X&CV?[J;_5+_RS
M-=##:V]N\CPPI&TAW.57&X^]8FD?\@>S_P"N2T 3?:!_SRG_ ._9H^T#_GE/
M_P!^S4U% $/V@?\ /*?_ +]FC[0/^>4__?LU-10!#]H'_/*?_OV:/M _YY3_
M /?LU-10!#]H'_/*?_OV:/M _P">4_\ W[-344 0_:!_SRG_ ._9H^T#_GE/
M_P!^S4U% $/V@?\ /*?_ +]FC[0/^>4__?LU-10!#]H'_/*?_OV:/M _YY3_
M /?LU-10!#]H'_/*?_OV:/M _P">4_\ W[-344 0_:!_SRG_ ._9H^T#_GE/
M_P!^S4U% $/V@?\ /*?_ +]FC[0/^>4__?LU-10!#]H'_/*?_OV:/M _YY3_
M /?LU-10!#]H'_/*?_OV:/M _P">4_\ W[-344 0_:!_SRG_ ._9H^T#_GE/
M_P!^S4U% $/V@?\ /*?_ +]FC[0/^>4__?LU-10!#]H'_/*?_OV:/M _YY3_
M /?LU-10!#]H'_/*?_OV:/M _P">4_\ W[-344 0_:!_SRG_ ._9H^T#_GE/
M_P!^S4U% $/V@?\ /*?_ +]FC[0/^>4__?LU-10!#]H'_/*?_OV:/M _YY3_
M /?LU-10!#]H'_/*?_OV:/M _P">4_\ W[-35S6L>+%TV_-K#;B8H,2%B5VM
MZ#UK.I4C35Y,B=2,%>1OFY55+-',% R28S@"L]M>M)]/NY[&1IFAC)XC. <<
M9S7,ZCXPFO=-EMA:"%I1M9PY/R]\<54OO#T^GZ/!J7G<.J^9'C:4W=/K7)/%
M7O[-726IRSQ-[^S5TEJ=9X=U2XO])$]T'DE\QEW)%Q@8]*U?M _YY3_]^S7'
M>$]>AM$339D;][-\D@(P">Q_'^==O6^&J*=-:W?4VH34Z:UU(?M _P">4_\
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ME/\ ]^S3[202:K#A)%Q%)]Y2.ZT^B#_D*0?]<I/YI0!JT444 %%%% !1110
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M.GT'3%:BVML@PMO"!G.!&.M2T5O&G&*M%&L81BK)"  #   ]A2T45984444
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MM?\ O\O^- %FBJW]HV/_ #_6O_?Y?\:/[1L?^?ZU_P"_R_XT 6:*K?VC8_\
M/]:_]_E_QH_M&Q_Y_K7_ +_+_C0!9HJM_:-C_P _UK_W^7_&C^T;'_G^M?\
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MP.>GXX[UH9LI-*.V**:R:,@QQ)O5E[@*!S]* ,329;V?4_WF%0R/YBO) P=
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MW*_=Y8YS@ "MS4/LD'E7]R75K<[49 68[R%VX&2<G;QZXH IZ(9'\^.9T>-
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MI9L+S5KN_MY('F*B-?)FW!HS@[F7LQ;(^@%0ZO?6.F?;%\AVGN"K%'C?RY&
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M]\)H?D56W(26!;)&WL1M//<D=JZNJ\-E%!=3W*[VFFP&9F)PHSA1Z 9)_$T
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M/:_;7%K!X:MYHI\6HMD\N2Y;J"H"[S^6:FN='L+N9Y9H3O< 2;)&02 ?W@"
MWXYJZB+&BHBA548"@8 % '#^#HGBU8K%+&T*VY#JC1[5SLP%"G/!#CTP%/>K
MWB>Y0ZA;QK=P2"-2LEF3*6WN5$;8BY'.1S_>XKHS90G4!>MO:98S&F6.U03D
MX'3)P,_05#>Z-I^H,'N;5&D!5A(N5<$'(^88/! [T 1:2FIQ:'$EXT4E\L8
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M&&V,5)'<9'KTI7M+:6V%M)!') H $;J&&!TX- ',>&?MSW[RQ&$6 7RY5 F
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MJH3M4_04 5O$\D T2:&:2!?.*J!-CD!@3@'@L "1GC.*H>#%E%O=[Y5ECW(
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=%% !1110 4444 %%%% !1110 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
